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Abstract 
This translational research piece involved collaborating with a local community 
mental health agency to examine knowledge, skills, attitudes, practices, and outcomes 
for panic disorder treatments. The project included designing and administering an 
online survey to client care personnel including psychologists, counselors, social 
workers, nurses, and psychiatrists. Additionally, a database review was utilized to 
obtain information about treatment modalities, duration, and outcomes. Survey results 
were analyzed using goodness of fit statistics to show differences between attitudes of 
participants by discipline regarding the safety and effectiveness of panic disorder 
treatments. The database analysis of pre and post GAF scores revealed comparable 
outcomes for therapy alone and therapy and medication treatment groups. 
Additionally, clients receiving therapy and medication for panic disorder were shown 
to have had significantly longer treatment duration on average than those in therapy 
only. These findings were discussed in terms of existing literature on panic disorder 
treatment and organizational change to make recommendations for the participating 
agency and others like it.    
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Diffusion of Innovative Panic Disorder Treatment Strategies in a Community 
Mental Health Agency 
Summary of Problem 
The following dissertation has been developed in response to obstacles 
encountered in implementing standardized panic disorder treatment protocols in a large 
metropolitan community mental health agency.  A large number of studies have been 
conducted that appear to support the efficacy of Cognitive-Behavioral Therapy (CBT) for 
managing the symptoms of panic disorder and decreasing dependency on psychotropic 
medications for the treatment of anxiety (Gould, Otto, & Pollack, 1995; Otto et al., 1993; 
Spiegel, Bruce, Gregg, & Nuzzarello, 1994).  However, there seems to be a dearth of 
translational research that could aid community mental health agencies in understanding 
the procedures of successfully navigating the process of implementing an innovative 
program for addressing the need for a balanced practice to treatment of anxiety disorders 
in a real practice setting.   
Panic disorder, an anxiety diagnosis that is characterized by recurrent unexpected 
panic attacks, is one of the most commonly treated mental health issues (American 
Psychiatric Association, 2000; Kessler, Berglund, Demler, Jin, & Walters, 2005; World 
Health Organization, 1998).  Although community population samples have been found 
to have lifetime prevalence rates of between one and two percent for this diagnosis, 
clinical populations report a much higher rate of about 10 percent lifetime prevalence.  
Additionally, Kessler and colleagues’ National Comorbidity Survey Replication (NCS-
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R), which reported prevalence findings based on symptom report as opposed to diagnosis, 
revealed a higher rate of 4.7 percent lifetime prevalence for the general U.S. population. 
Individuals with anxiety disorders frequently exhibit the mental and physiological 
reactions associated with fear in response to non-threatening stimuli and situations 
(American Psychiatric Association, 2000; World Health Organization, 1998).  This is 
particularly common for individuals with panic disorder, whose fear of recurrent panic 
attacks can lead to restrictive behavioral patterns.  These individuals may also develop 
symptoms of agoraphobia, a fear of going outside or being among crowds of people, due 
to apprehension about being in public settings where they cannot escape or control a 
possible panic attack. Consequently, they often develop avoidance strategies that interfere 
with social and occupational functioning.  The course of panic disorder may be either 
constant or episodic, but it is almost always chronic.  Therefore, it requires treatment 
methods that can deliver sustainable improvement.  
Current recommended treatment practices for panic disorder include 
pharmacological treatments, behavioral health interventions, or a combination of these 
modalities (American Psychiatric Association, 2009; World Health Organization, 1998).  
Pharmacological intervention generally includes the use of benzodiazepine, Selective 
Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor 
(SNRI), or Tricyclic Antidepressant (TCA) prescriptions for the management of panic 
attack symptoms.  Behavioral healthcare interventions designed for the treatment of panic 
disorder include CBT with exposure techniques, Panic Focused Psychodynamic 
Psychotherapy (PFPP), and Emotion-Focused Psychotherapy for Panic Disorder 
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(EFPPD) (Barlow, 2002; Milrod, Busch, Cooper, & Shapiro, 1997; Milrod et al., 2007; 
Shear, Houck, Greeno, & Masters, 2001).   
Antidepressant medications such as TCAs (imipramine and clomipramine), SSRIs 
(fluoxetine, sertraline, escitalopram, fluvoxamine, and paroxetine), and SNRIs 
(venlafaxine) have generally received favorable reviews in clinical trials for the treatment 
of panic disorder.  A number of studies using a variety of antidepressants have found a 
decrease in the rates of panic attacks for participants when compared to those given a 
placebo, and these findings appear to be sustained for the duration of the pharmacological 
treatment (Hoehn-Saric, McLeod, & Hipsley, 1993; Pollack et al., 2007; Sheikh, 
Londborg, Clary, & Fayyad, R. 2000).  However, it appears that troublesome side effects 
such as those related to sexual dysfunction or weight gain may lead to premature and 
abrupt termination of antidepressant treatments (American Psychiatric Association, 
2009).  Cessation of the antidepressant medication is usually associated with a return of 
panic attacks, as well as bothersome discontinuation syndrome symptoms including 
gastrointestinal and sleep disturbances in the case of abrupt termination of 
pharmacological treatment.   Additionally, some research suggests that the use of an 
antidepressant medication treatment regimen may lead to an increase in the risk for 
suicide and self-harm, and the potential benefits and risks should be evaluated by 
considering all of the above factors (Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 
2005). 
The use of benzodiazepines such as lorazepam (Ativan), clonazepam (Klonopin), 
and alprazolam (Xanax) to treat panic disorder appears to be an effective treatment 
strategy so long as the client continues to take the medication as prescribed; however, 
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discontinuation often leads to relapse and bothersome symptoms of withdrawal in cases 
of abrupt cessation (American Psychiatric Association, 2009; Otto, Smits, & Reese, 
2006).  Several possible problems have been identified related to the use of 
benzodiazepines for the treatment of panic disorder.  For example, some studies have 
shown that benzodiazepines can interfere with the effectiveness of Cognitive-Behavioral 
Therapy (Barlow, 2002; Barlow, Gorman, Shear, & Woods, 2000).  Specifically, it is 
theorized that they superficially attenuate feelings of anxiety and impede clients from 
benefiting from exposure based treatment interventions that require that the aversive 
reactions be fully experienced in order to truly extinguish that response.  Additionally, 
other safety concerns that must be considered include the development of physical 
dependence and abuse of the medication, increased health and safety risks for elderly 
clients, and potentially life-threatening drug or alcohol interactions (American Psychiatric 
Association, 2009; Ciraulo, & Nace, 2000; Ciraulo, Sands, & Shader, 1988; French et al., 
2005; Kelly, Darke, & Ross, 2004;  Landi et al., 2005) 
Behavioral health interventions that have been developed for the treatment of 
anxiety include: CBT with exposure techniques, PFPP, and EFPPD (Barlow, 2002; 
Milrod, Busch, Cooper, & Shapiro, 1997; Milrod et al., 2007; Shear, Houck, Greeno, & 
Masters, 2001).  There is little research regarding the efficacy of the supportive form of 
counseling utilized in EFPPD.  Preliminary findings appear to indicate that it is not as 
effective as treatment with pharmacological intervention or CBT treatment strategies in 
reducing incidence of panic attacks; however, it appears to be superior to 
pharmacological intervention in treatment retention rates (Shear, Houck, Greeno, & 
Masters, 2001).  PFPP emphasizes the importance of articulation of the relationship 
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between the therapist and client, and of understanding the psychological significance of 
panic and phobic avoidance (Milrod, Busch, Cooper, & Shapiro, 1997; Milrod et al., 
2007).  This method of treatment has demonstrated preliminary comparable efficacy in 
the treatment of panic disorder as CBT.  CBT treatment of panic disorder is generally 
highly structured and usually includes homework that utilizes exposure exercises 
involving anxiety provoking stimuli to promote eventual extinction of the panic response 
(Barlow, 2002; Barlow, Gorman, Shear, & Woods, 2000).   There is significant evidence 
that CBT is a more tolerable treatment compared to medications that frequently have 
bothersome side effects, and it is more cost-effective when the long-term outcomes such 
as strong relapse-prevention effects are considered (American Psychiatric Association, 
2009; Barlow, 2002; Barlow, Gorman, Shear, & Woods, 2000). 
Despite the above cited evidence for the effectiveness of behavioral treatment 
methods, the community mental health agency being examined in this study has reported 
an alarming rate of ongoing benzodiazepine prescriptions.  This is not necessarily unique 
to this agency, which is generally a very strong community mental health center.  The 
extensive use of benzodiazepine prescriptions nationally in both primary care and in 
agency settings has drawn growing attention (Bruce, Vasile, & Goisman, 2003; Smith, 
Sketris, Cooke, Gardner, Kisely, & Tett, 2008).  This agency is being used in essence as a 
“case in point” for the study of current practice and the potential for systemic change in 
future practice.  Within this treatment agency, possible issues that have been identified 
related to the use of benzodiazepines for the treatment of panic disorders include: 
interference with behavioral treatment interventions, the development of physical 
dependence, the possibility of abuse or sale of the medication, increased health and safety 
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risk for elderly clients, potentially life-threatening drug or alcohol interactions, and 
wasted clinic resources due to an increased rate of no show/cancellations for therapy 
sessions.  Therefore, this study has been approved by the agency to elucidate the potential 
benefits and dilemmas for implementing innovative best practice standards for the 
treatment of panic disorder.  
Aim and Purpose 
The aim of this study was to collect a profile of knowledge, skills, attitudes, and 
current practices within a large community mental health agency in order to examine the 
potential options and dilemmas involved in implementing innovative or best practice 
guidelines for the treatment of panic disorder.  This study utilized methods including 
database analysis and record review to formulate an accurate profile of the agency’s 
current treatment practices.  Additionally, a computerized survey with categorical and 
Likert type scaled items was administered to key subgroups that influence client care. 
The resulting data were used to provide information regarding the organization’s view of 
the potential need for innovative panic disorder treatment practices and possible obstacles 
or impediments for implementing changes in treatment standards.  Specifically, the 
information gathered through these methods was used to formulate answers for three 
research questions:  (a) To what extent are there differences in current recommendations, 
reported practices, and reported knowledge or skills for the treatment of panic disorder at 
the community mental health agency being studied?  (b) To what extent are there 
differences between or within agency cohorts defined by professional affiliation and 
educational attainment level as it relates to knowledge, practices, and attitudes regarding 
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the treatment of panic disorder?  (c) To what extent are treatment outcome variables 
related to the type of panic disorder treatment that clients receive?   
Successive chapters present a review of the current literature base regarding the 
nature of panic disorder with a critical evaluation of current best practice standards for 
treatment.  The next chapter is devoted to the examination of literature related to 
organizational change models with a focus on diffusion of innovations and successful 
program implementation in community mental health settings.  A chapter that details the 
current study includes a description of the institution being studied, the resources utilized 
for this research, and the methods of investigation.  Finally, qualitative and quantitative 
results are discussed in light of organizational change literature and what current results 
imply regarding successful treatment strategies for panic disorder in a community mental 
health setting.   
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Literature Review 
Panic Disorder 
 Panic disorder is a condition characterized by recurrent unexpected panic attacks 
that are not due to the direct physiological effects of a substance or a general medical 
condition (American Psychiatric Association, 2000; World Health Organization, 1998).  
A panic attack is defined as an episode of intense fear or discomfort in the absence of real 
danger that is accompanied by physical symptoms.  Examples of these somatic symptoms 
are tightness or pain in the chest, shortness of breath, pounding or racing heart, sweating, 
shaking, nausea, dizziness, or bodily sensations such as tingling, numbness, or hot or cold 
flushes.  The current diagnostic criteria specify that the individual has had at least two 
attacks, and one of those attacks must have resulted in at least a month of persistent 
cognitive or behavioral disturbance due to anxiety regarding the experience.  Panic 
attacks also commonly occur with other anxiety disorders; however, those attacks occur 
primarily in response to a feared situation or stimuli.  Panic attacks that occur during the 
course of panic disorder are described as unexpected, meaning that the individual cannot 
readily identify an associated situational trigger.  For persons with panic disorder, the 
anxiety provoking stimuli are the psychological, physical, and feared consequences of the 
attacks themselves.     
The psychological experiences of impending doom, loss of control, and going 
crazy that accompany panic attacks can lead to persistent and disruptive worry about 
experiencing another episode (American Psychiatric Association, 2000; World Health 
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Organization, 1998).  This may lead to a catastrophic misinterpretation bias that can 
cause individuals with panic disorder to perceive benign bodily sensations such as 
increased respirations or heart rate as signs that they are experiencing a heart attack or 
some other life threatening ailment (American Psychiatric Association, 2000; Rosmarin, 
Bourque, Antony, & McCabe, 2009).  Some individuals may become convinced that the 
somatic sensations associated with the attacks are signs of an undiagnosed medical 
condition and repeatedly seek confirmation of these fears by consulting physicians for 
testing.  Additionally, the unexpected and intense somatic sensations and cognitive 
activation associated with panic attacks may cause individuals to feel as though they are 
losing control or going crazy, and many individuals with panic disorder report a fear that 
they may vomit, faint, or experience an incontinent episode in public as a result of an 
attack.  Although at least one study has shown that these events rarely actually occur with 
panic attacks, the catastrophic fears of public humiliation can be powerful and 
debilitating for individuals with panic disorder (Green, Antony, McCabe, & Watling, 
2007).   
Behavioral changes associated with the diagnosis of panic disorder are typically 
the result of attempts to avoid future attacks and public embarrassment (American 
Psychiatric Association, 2000; Batelaan, Graaf, Penninx, Balkom, Vollebergh, & 
Beekman, 2009).  Unfortunately, individuals that restrict physical exertion, social 
contact, and exposure to anxiety provoking situations to reduce the risk of experiencing 
another panic attack are also likely to experience disruptions in their occupational, 
educational, or familial functioning.  The resulting interpersonal relationship difficulties 
likely contribute to the increased incidence of comorbidities including major depressive 
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disorder, substance abuse, and other anxiety disorders for individuals with panic disorder.  
Additionally, if this anxiety leads to avoidance of many situations and severely effects 
day-to-day life, panic disorder with agoraphobia may be diagnosed.  About one-third to 
one-half of persons diagnosed with panic disorder in community samples met criteria for 
agoraphobia, but the numbers for clinical sample are believed to be much higher.        
 Overall, the prognosis for individuals diagnosed with panic disorder appears to 
vary greatly depending on factors such as severity and frequency of attacks, educational 
level, and presence of comorbid conditions (American Psychiatric Association, 2000; 
Batelaan, Graaf, Penninx, Balkom, Vollebergh, & Beekman, 2009).  Most longitudinal 
research has been conducted in tertiary care settings and indicates that the usual course is 
chronic, with either continuous symptom presentation, or discrete periods of remission 
and recurrence (American Psychiatric Association, 2000; Goodwin et al., 2005; Pollack 
and Smoller, 1995).  However, studies that have focused on general population samples 
have shown greater variations in the course of the disorder and better overall prognosis 
(Batelaan, Graaf, Penninx, Balkom, Vollebergh, & Beekman, 2009; Eaton et al., 1998).   
Treatments  
 Treatment recommendations for panic disorder generally include either the use of 
behavioral health interventions such as therapy or pharmacological treatment in the form 
of benzodiazepine or antidepressant medications (American Psychiatric Association, 
2009; World Health Organization, 1998).  Additionally, there is an ongoing debate in the 
mental health field about the usefulness of combining pharmacological and behavioral 
health strategies in an attempt to capitalize on potential benefits of both treatment 
modalities (Barlow et al., 2000; Westra and Stewart, 1998; Uhlenhuth et al., 1999).  
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However, there is an apparent lack of consensus or precise guidelines to clarify the 
decision making process of choosing the best method of treatment for individuals with 
panic disorder (Starcevic, Linden, Uhlenhuth, Kolar, & Latas, 2004; Beamish, Granello, 
& Belcastro, 2002; Pollack, 2006). Therefore, the potential benefits and risks of each 
treatment option must be considered with respect the individual client’s situation and 
needs.        
Pharmacological interventions.  Medications from several different classes have 
been used to stop or reduce the frequency of panic attacks for over 40 years, and current 
practice   guidelines in pharmacological intervention recommend the use of 
antidepressants or benzodiazepine prescriptions for the management of panic disorder 
symptoms (American Psychiatric Association, 2009; World Health Organization, 1998).  
Specifically, benzodiazepines and antidepressant drugs are the currently most commonly 
prescribed anxiolytic agents.  Antihypertensive, anticonvulsant, antipsychotic, and older 
generation antidepressant medications such as Monoamine Oxidase Inhibitors (MAOIs) 
have also been used by some practitioners for the treatment of panic related symptoms; 
however, research regarding these medications has shown the potential for serious 
medical side effects such as liver failure.  The addition of limited favorable research 
results and the existence of contradictory findings have caused the American Psychiatric 
Association (2009) to not recommend such off-label prescription practices.  Therefore, 
the focus of this literature review will be limited to the risks and benefits of Selective 
Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor 
(SNRI), Tricyclic Antidepressant (TCA), and benzodiazepine medications for the 
treatment of panic disorder.   
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Antidepressants.  Antidepressant medications have shown clinical efficacy in the 
reduction of number and severity of reported panic attacks, and they have the added 
benefit of offering pharmacological coverage for symptoms associated with mood 
disorder comorbidities without concerns about dependency or liability for abuse 
(American Psychiatric Association, 2009; Pollack, 2006).  Three types of antidepressants 
are currently recommended as first-line pharmacological treatment options for panic 
disorder.  Those medication classes are referred to as TCAs, SSRIs, and SNRIs.   
The use of TCAs for the management of panic attacks dates back to 1964, when a 
trial by Klein (1964) showed that imipramine (Tofranil) was superior to placebo for 
reducing panic symptoms.  Multiple studies have replicated these findings (Barlow, 
Gorman, Shear, & Woods, 2000; Mavissakalian & Perel, 1985; Pollack, Otto, Sachs, 
Leon, Shear, Deltito, Keller, & Rosenbaum, 1994; Uhlenhuth, Matuzas, Glass, & Easton, 
1998).  The results from these studies have shown that after treatment with imipramine 
45%-70% of patients were found to be panic free, compared to 15%–50% of those 
receiving placebo.  Additional findings included that patients with panic disorder who 
were treated with imipramine appeared to exhibit less agoraphobic avoidance and 
anticipatory anxiety than those receiving placebo. 
A number of studies that have utilized placebo-controlled randomized trials 
support the acute and long-term efficacy of clomipramine (Anafranil) for the 
management of panic disorder symptoms (Bakker, van Dyck, Spinhoven, & van 
Balkom,1999; Fahy, O'Rourke, Brophy, Schazmann, & Sciascia, 1992; Johnston, Troyer, 
Whitsett, & Dalby, 1995).  In fact, research appears to suggest that clomipramine is at 
least as effective as imipramine and possibly superior in preventing panic attacks 
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(Cassano, Petracca, Perugi, Nisita, Musetti, Mengali, & McNair, 1988; Modigh, 
Westberg, & Eriksson,1992).  Moreover, most placebo-controlled studies comparing 
clomipramine to Selective Serotonin Inhibitors also demonstrate equivalent efficacy in 
treating panic disorder; however, there appears to be a less favorable side effect profile 
for the TCAs when compared to SSRIs (American Psychiatric Association, 2009; 
Bakker, van Dyck, Spinhoven, & van Balkom,1999).  
Many side effects of TCAs such as dry mouth, dry nose, blurry vision, 
constipation, urinary retention, memory impairment, and increased body temperature are 
likely related to their effect on acetylcholine receptors (Physician’s Desk Reference, 
2007). Other side effects may include drowsiness, anxiety, anhedonia, confusion, 
restlessness, dizziness, changes in appetite and weight, sweating, sexual dysfunction, 
weakness, nausea and vomiting, hypotension, tachycardia, and rarely, irregular heart 
rhythms. Unfortunately, side effects are relatively common especially during the first few 
weeks of treatment (Pollack, 2006).  Although dosage of the medication can be titrated up 
to a therapeutic level in an attempt to stem these effects, this also has the effect of 
delaying treatment benefits.  Mavissakalian and Perel (1997) reported that due to these 
bothersome side effects they found a higher dropout rate when higher doses of TCAs 
were prescribed in their study.  However, such abrupt cessation of TCAs is generally 
discouraged because it can result in discontinuation syndrome symptoms such as anxiety, 
insomnia, headache, nausea, malaise, or motor disturbance (American Psychiatric 
Association, 2009; Physician’s Desk Reference, 2007). 
Numerous large clinical trials have indicated that SSRIs including sertraline 
(Zoloft), fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), citalopram 
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(Celexa), and escitalopram (Lexapro) are all effective for the acute and long-term 
management of panic disorder (Hoehn-Saric, McLeod, & Hipsley, 1993; Leinonen et al., 
2000; Lepola et al., 1998; Michelson et al., 2001; Michelson et al., 1999; Pohl, Wolkow, 
& Clary, 1998; Pollack et al., 2007; Sheikh, Londborg, Clary, & Fayyad 2000; Stahl, 
Gergel, & Li, 2003).  Although an early meta-analysis by Boyer (1995) suggested that 
improvement with SSRIs treatment for panic disorder was significantly greater than for 
alprazolam or imipramine, a subsequent meta-analysis incorporating a larger number of 
studies showed comparable efficacy for the SSRIs and TCAs (Otto, Tuby, Gould, 
McLean, & Pollack, 2001).  However, this later study showed mixed results regarding the 
question of whether dropout rates were lower in studies in which patients received SSRIs 
versus TCAs.  Taken together, this research suggests that SSRIs are likely at least as 
effective as TCAs and benzodiazepines in the treatment of panic disorder with possibly 
fewer associated side effects.    
Venlafaxine extended release (Effexor) is the only SNRI that has met the criteria 
by the American Psychiatric Association (2009) for recommendation as a treatment of 
panic disorder symptoms.  Numerous studies have shown it to be as effective as other 
antidepressant medications in treating panic disorder Symptoms.  For example, 
Bradwejn, Ahokas, Stein, Salinas, Emilien, and Whitaker (2005) conducted a large 
multicenter study of individuals with panic disorder that demonstrated that a 10-week 
course of venlafaxine ER (extended release) resulted in a significantly greater reduction 
in frequency of panic attacks than placebo.   
Another large multicenter trial included a comparison of the effectiveness of 
venlafaxine ER, paroxetine (Paxil), and placebo for the treatment of panic disorder 
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without co-occurring depression (Pollack, Lepola, Koponen, Simon, Worthington, 
Emilien, Tzanis, Salinas, Whitaker, & Gao, 2007). The results of this study showed both 
paroxetine and venlafaxine were significantly more effective than placebo in reducing the 
number of panic attacks experienced by participants. Additionally, there were no 
significant differences between the venlafaxine ER or paroxetine treatment groups in 
terms of efficacy or reported side effects with the exception of somewhat less sedation 
reported by the venlafaxine ER than paroxetine treatment group.   
Although venlafaxine is the only Serotonin Norepinephrine class medication 
currently recommended for the treatment of panic disorder, duloxetine (Cymbalta) is 
similar to venlafaxine in its chemical mechanism of action and is currently being 
investigated as another potential anxiolytic (American Psychiatric Association, 2009).  It 
has shown comparable results in preliminary research for its use in the treatment of panic 
disorder (Serretti, Chiesa, Calati, Perna, Bellodi, & De Ronchi, 2010).  However, further 
research is needed to replicate these preliminary findings before it can be deemed a safe 
and effective pharmacological treatment option. 
The use of serotonergic antidepressants can result in several bothersome side 
effects (Physician’s Desk Reference, 2007; Pollack, 2006).  These symptoms may 
include, but are not limited to, dizziness, headache, apathy, sexual dysfunction, weight 
gain, nausea, as well as disturbances in appetite and sleep.  Side effects are most 
commonly reported in the first few weeks of treatment, and some individuals also report 
an exacerbation in jitteriness and anxiety during that period.  To counteract these 
concerns, dosage is usually started at a lower rate and then titrated up to the therapeutic 
level. However, these medications are slow acting to begin with, usually taking between 
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6 to 8 weeks to reach effectiveness, and this process may prolong the time it takes for 
individuals to start feeling some relief from their panic symptoms.  Additionally, if 
troublesome side effects or impatience lead to premature termination of antidepressant 
treatments, a discontinuation syndrome and return of the panic attack may result 
(American Psychiatric Association, 2009).  For example, studies show that abrupt 
discontinuation of antidepressants can result in withdrawal symptoms such as 
incoordination, headache, irritability, and nausea from participants (Shelton, 2006; 
Schatzberg, Blier, Delgado, Fava, Haddad, & Shelton, 2006).  Additionally, research 
suggests that the use of antidepressants may lead to an increased risk for suicide and self 
harm is another important factor to consider in recommending a treatment for individuals 
with panic disorder (Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 2005). 
Another concern regarding the use of antidepressants for the treatment of panic 
disorder is that few data suggest an optimum length of treatment following reduction in 
symptoms (American Psychiatric Association, 2009).  Studies using varying 
antidepressant agents have shown that relapse is more common after discontinuation of 
the medication when comparing continued medication treatment groups and those tapered 
with placebo.  Thus, it appears that antidepressants are effective for the management of 
panic disorder symptoms only as long as the medication is continued.  
Benzodiazepines.  Alprazolam (Xanax) has been FDA approved for the treatment 
of panic disorder, and it has been studied more extensively than any other 
benzodiazepine. In numerous studies alprazolam has been shown to be superior to 
placebo in reducing frequency and severity of panic attacks (Dunner, Ishiki, Avery, 
Wilson, & Hyde, 1986; Chouinard, Annable, Fontaine, & Solyom, 1982; Tesar et al., 
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1991).  Specifically, the studies indicated that about 55% to 75% of participants treated 
with alprazolam reported a reduction in panic levels versus about 15% to 50% for the 
placebo group participants.  In another study alprazolam demonstrated comparable results 
in alleviating panic symptoms with lower treatment dropout rates when compared to the 
TCA imipramine (Tofranil) (Charney et al., 1986).  Additionally, numerous studies 
supporting the short-term efficacy of other benzodiazepines such as clonazepam 
(Klonopin), diazepam (Valium), and lorazepam (Ativan) have also been published 
(Dunner, Ishiki, Avery, Wilson, & Hyde,1986; Charney, & Woods, 1989; Tesar et al. 
1991; Schweizer, Pohl, Balon, Fox, Rickels, & Yeragani, 1990).  These studies generally 
showed a consensus that various benzodiazepine agents demonstrated comparable levels 
of symptom reduction rates to those attained by participants treated with alprazolam or 
imipramine.  
Although consideration of comorbidities is an important step in selecting a 
pharmacological agent for the treatment of clients with panic disorder, most of the above 
studies excluded participants with a history of diagnosed mood disorders.  
Benzodiazepines appear to be ineffective for treatment of mood disorders and may 
exacerbate symptoms of depression (Pollack, 2006).  However, despite recommendations 
from clinical practice guidelines to use antidepressants as first-line pharmacotherapy for 
panic disorder, data from the prospective longitudinal Harvard/Brown Anxiety Research 
Project showed that most patients treated for panic disorder were still receiving 
benzodiazepines (Bruce, Vasile, & Goisman, 2003).   
Commonly reported side effects of benzodiazepines include sedation, fatigue, 
ataxia, slurred speech, memory impairment, and weakness (Physician’s Desk Reference, 
 
18 
 
2007).  Research has also suggested that individuals treated with benzodiazepines may be 
at risks for increased incidence of motor vehicle accidents and a heightened risk of falls 
and fractures for geriatric clients (French, et al., 2005; Kelly, Darke, & Ross, 2004; 
Landi, et al., 2005).  Additionally, the administration of benzodiazepines for more than 2 
to 3 weeks results in physiologic dependence, and withdrawal symptoms such as 
insomnia, gastrointestinal problems, tremors, agitation, fearfulness, and muscle spasms 
often occur in the case of discontinuation (Physician’s Desk Reference, 2007; Pollack, 
2006).  Moreover, abrupt cessation of benzodiazepines can result in dangerous side 
effects including depression, suicidal behavior, psychosis, seizures, and delirium tremens; 
therefore, a physician managed gradual taper is recommended.  Due to issues related to 
withdrawal symptoms and rebound panic symptoms individuals often experience 
difficulty discontinuing benzodiazepines (Klein, Colin, Stolk, & Lenox, 1994; Roy-
Byrne, et al., 2003).  Specifically, a study by Fava and colleagues (1995) found that about 
30% of participants that received benzodiazepines as part of their treatment regimen were 
unable to completely taper off of benzodiazepines use during the treatment period. 
Taken together, this literature review yields important information about the 
effectiveness and general recommendations regarding pharmacological treatment of panic 
disorder.  Although antidepressants and benzodiazepines appear to be effective in 
reducing panic symptoms, both of these classes of medication are also associated with 
specific side effects, safety concerns, and limitations in post treatment response 
durability.  Specifically, whereas antidepressants offer pharmacological coverage for 
symptoms associated with mood disorder comorbidities without concerns about 
dependency or liability for abuse,  benzodiazepines appear to be ineffective for treatment 
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of comorbid mood disorders and may actually exacerbate symptoms of depression 
(American Psychiatric Association, 2009; Pollack, 2006).  On the other hand, 
antidepressants appear to take longer to achieve symptom reduction, have less tolerable 
preliminary side effect profiles, and they may cause an initial exacerbation in anxiety 
levels.  Moreover, cessation of either benzodiazepines or antidepressants has been shown 
to result in the development of a discontinuation syndrome that could further complicate 
treatment regimens that incorporate the use of these anxiolytic agents.  Therefore, it is 
recommended that all of these factors be considered when formulating an individualized 
treatment plan for clients with panic disorder.  Interestingly, despite current clinical 
practice guideline recommendations that indicate the use antidepressants as first-line 
pharmacotherapy for panic disorder, recent longitudinal research revealed that most 
patients treated for panic disorder were still receiving benzodiazepines (Bruce, Vasile, & 
Goisman, 2003).   
Behavioral health interventions.  Most research that has been conducted on the 
implementation of behavioral health interventions for the treatment of panic disorder has 
focused specifically on Cognitive-Behavioral Therapy (CBT) (American Psychiatric 
Association, 2009).  Although there is a relative dearth of research with respect to 
alternative behavioral health interventions for the treatment of panic disorder, some other 
therapeutic approaches that have been investigated include Panic Focused 
Psychodynamic Psychotherapy (PFPP) and Emotion-Focused Psychotherapy for Panic 
Disorder (EFPPD).  The state of research reviewed on PFPP and EFPPD has been 
described as preliminary at best; however, a brief examination of the literature regarding 
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the practices and outcomes these two modalities of therapy can provide an informative 
point of comparison for considering the use of CBT techniques.   
 Cognitive-Behavioral Therapy.  In terms of CBT, panic disorder is 
conceptualized as a maladaptive pattern of thoughts and behaviors that initiate, sustain, or 
exacerbate panic symptoms (Sokol, Beck, Greenberg, Wright, & Berchick, 1989).  Thus, 
the goal is to reduce the fear and avoidance of external and internal cues that have 
become associated with panic attacks. This is typically accomplished through a 
combination of cognitive restructuring and exposure techniques.  Cognitive restructuring 
usually focuses on correcting tendencies to catastrophize situations or sensations.  
Additionally, behavioral techniques such as interoceptive exposure or inducing of 
somatic sensations associated with panic attacks, as well as situational exteroceptive 
exposure are used to desensitize clients to panic symptoms.  The standard recommended 
CBT treatment regimen consists of 12 weekly sessions; however, the American 
Psychiatric Association (2009) notes that time saving alternative intervention methods 
such as telephone or computer assisted therapy are possible avenues that merit further 
research.   
Numerous studies have demonstrated the efficacy of using CBT for the treatment 
of panic disorder (Barlow, Gorman, Shear, & Woods, 2000; Barlow, Craske, Cerney, & 
Klosko, 1989; Clark, Salkovskis, Hackmann, Middleton, Anastasiades, & Gelder, 1994; 
Craske, Brown & Barlow, 1991; Craske, DeCola, Sachs, & Pontillo, 2003; Craske, Lang, 
Aikins, & Mystkowski, 2005; Telch, Lucas, Schmidt, Hanna, LaNae, & Lucas 1993).  
Additionally, several meta-analyses of clinical trials have also supported the use of CBT 
for panic disorder (Gould, Otto, & Pollack, 1995; Butler, Chapman, Forman, & Beck, 
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2006; Mitte, 2005).  Barlow et al. (2000) conducted the largest of these trials which 
included 312 individuals who had been diagnosed with panic disorder. They compared 
treatment groups that received CBT, imipramine (Tofranil), CBT and imipramine, CBT 
and placebo, and placebo.  They found that CBT was superior to placebo and comparable 
to imipramine alone and CBT with imipramine combination intervention in reducing 
panic symptoms at the end of the acute phase of treatment.  After a 6-month maintenance 
phase of continued medication and monthly CBT booster sessions, CBT alone was again 
found to be superior to placebo and equivalent to imipramine.  The combination of CBT 
and imipramine treatment was found to be significantly superior to all other treatment 
conditions at the end of this phase of the study. However, at the end of a 6-month follow-
up phase after termination of all treatments the CBT and CBT plus placebo were the only 
two treatment conditions that remained superior to placebo.  Thus, this study 
demonstrated the short and long-term efficacy of CBT for the treatment of panic disorder, 
and it suggests that CBT without adjunctive pharmacological treatment is most likely to 
produce durable reduction in panic symptoms.  Additionally, this finding of sustained 
beneficial effects for individuals who showed reduced panic symptoms as a result of 
treatment with CBT has been replicated in other studies (Brown & Barlow, 1995; Craske, 
Brown, & Barlow, 1991; Fava, Zielezny, Savron, Grandi, 1995).  
 Psychodynamic Psychotherapy.  Aside from the numerous studies concerning the 
use of CBT techniques, there has been relatively little research conducted regarding the 
effectiveness of other behavioral health interventions (American Psychiatric Association, 
2009).  One exception is a study that appears to support the effectiveness of PFPP for the 
treatment of panic disorder (Milrod et al., 2007).  PFPP is a brief panic focused 
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psychodynamic intervention model that consists of 24 bi-weekly sessions.  During the 
first phase of PFPP, the client and therapist work to uncover the unconscious meanings 
behind panic symptoms in order to achieve a reduction in panic attacks and agoraphobia.   
The second phase focuses on deepening the understanding of core unconscious conflicts 
and altering these beliefs through techniques such as analysis of transference.  Finally, in 
the third phase the client’s reaction to termination issues allows them to re-experience 
conflicts related to separation and anger.  Although a resurgence of panic symptoms may 
appear during this phase of treatment, articulating underlying feelings with the therapist 
is theorized to help clients identify new abilities to manage these emotions and promote 
autonomy.  In a randomized controlled trial Milrod et al. (2007) compared the 
effectiveness of PFPP and a manualized Behavioral Therapy program consisting of 
applied relaxation with exposure training for the treatment of panic disorder.  These 
authors found that 73% of participants that were treated with the PFPP techniques 
reported a significant reduction in panic symptoms versus 39% of those that were in the 
applied relaxation treatment group.  Although this is only a single study, the author 
proposed that these preliminary promising findings suggest that further research should 
explore whether PFPP could be a efficacious alternative to CBT in the treatment of panic 
disorder.  
Emotion-Focused Psychotherapy for Panic Disorder.  Another possible 
therapeutic treatment modality that has been investigated is EFPPD (Shear et al, 2001).  
EFPPD was described as a brief treatment consisting of empathic listening and supportive 
strategies that aim to help clients identify and manage painful emotions and troubling life 
situations.  These authors compared the outcomes for participants who participated in 
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EFPPD to treatment groups who received CBT, imipramine (Tofranil) prescription, or 
placebo.  The response rate for imipramine and CBT treatment groups, 93% and 82% 
respectively, showed comparable reductions in reports of panic symptoms.   Additionally, 
they found that the response rate for participants who received EFPPD was more similar 
to that of the placebo treatment group, at 52% and 63%.  One interesting caveat to this 
study was that despite the demonstrated superior effectiveness of CBT and imipramine in 
treating panic symptoms, treatment retention rates were highest for the EFPPD group.  
Specifically, the acute and maintenance treatment was completed by 60% of participant 
receiving EFPPD, 47% of those receiving CBT, 38% of those receiving placebo, and 
13% receiving imipramine.  It is not possible to determine if the differences in drop-out 
rates were due to drug side-effects, dissatisfaction with treatment results, or other factors 
related to treatment tolerability.  However, the authors of this study suggested that the 
lower attrition rate in conjunction with poorer response to treatment may actually be 
related to avoidant and separation-anxiety tendencies commonly encountered when 
treating individuals with panic disorder.  They concluded that practitioners should closely 
monitor effectiveness of the treatments they offer, and consider using CBT techniques in 
order to safeguard against colluding with possible avoidant behavior.       
Combination pharmacological and therapy intervention.  As detailed above 
both pharmacological and behavioral health interventions have demonstrated efficacy in 
reducing the symptoms associated with panic disorder.  It is not surprising then, that 
many mental health professionals advocate a treatment approach that combines the use of 
pharmacological and therapy interventions (Pollack, 2006).  Specifically, many mental 
health professionals and clients have sought to couple the fast relief of panic symptoms 
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brought on by benzodiazepines with the sustainable treatment gains that have become 
associated with CBT.  However, research suggests that combining these treatment 
modalities does not necessarily result in a beneficial additive effect.  Instead, findings 
indicate that CBT for the treatment of panic disorder with or without pharmacotherapy 
yields similar results (Barlow, Gorman, Shear, & Woods, 2000; Schmidt, & Smith, 2005; 
Westra, Stewart, and Conrad, 2002).  Furthermore, there is also research that suggests 
that the concurrent use of benzodiazepines with CBT actually results in fewer long-term 
treatment gains (Brown & Barlow, 1995; Fava, et al., 1995; Westra, et al., 2004).  Westra 
and colleagues’ study found that participants from the combined benzodiazepine and 
CBT treatment group retained about 20% less of the presented psychoeducational 
material than their nonmedicated counterparts.  Further, they found that chronicity and 
frequency of use were not related to memory, but that greater time from peak blood-drug 
concentration during the encoding task was associated with better recall.  This evidence is 
counter to beliefs that memory deficits associated with benzodiazepine use fade as 
physiological tolerance is established.  Additionally, Otto, Smits, and Reese (2006) 
asserted that a combination antidepressant and CBT approaches for individuals with 
panic disorder does not appear to have significant benefits over CBT alone, and CBT 
shows superior long-term effectiveness when compared to antidepressant medication and 
combined treatment groups.  In conclusion, it appears that combination therapy may 
significantly increase the cost, risks, and resources associated with treating pure panic 
disorders without substantial evidence that of superior acute or maintenance efficacy and 
limit the long-term gains.      
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Organizational Change 
 According to Rogers (2003) an organization is “a stable system of individuals 
who work together to achieve common goals through a hierarchy of ranks and a division 
of labor” (p. 433). Predetermined goals, prescribed roles, rules, regulations, interactional 
patterns, and configuration of authority are collectively known as the organizational 
structure.  This structure provides stability to the organization by encouraging individual 
members to behave in a predictable and acceptable manner.  However, the ability to cope 
with innovation or change such as restructuring, outsourcing, or incorporating the use of 
new techniques or technology, must also be a part of any viable organizational model 
(Prochaska, Levesque, Prochaska, Dewart, & Wing, 2001).  Since one of the aims of this 
dissertation is to function as a translational research piece that promotes agency change, a 
brief review of literature on diffusion of innovations and organizational change will be 
helpful in understanding the methods and goals of this project.      
Transtheoretical Model of Change.  The Transtheoretical Model of Change has 
its roots in research that addresses evaluating and affecting change readiness for 
individuals with addictive behavior problems, but it has more recently evolved into a 
popular integrative approach used to describe and promote individual and organizational 
change (Prochaska & DiClemente, 1983; Prochaska, DiClemente, & Norcross, 1992; 
Prochaska & Velicer, 1997).  Its most recent version integrates a variety of existing 
theoretical concepts including stage of change, decisional balance, self-efficacy, and 
processes of change (Bandura, 1977; Janis & Mann, 1977; Prochaska & DiClemente, 
1983; Prochaska & Velicer,1997).  The first core construct, Prochaska and Diclemente’s 
(1983) stage of change model, theorizes that people move through five distinct stages 
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when they modify behaviors.  These stages include:  (a) The Precontemplation Stage, 
which is characterized by the individual not intending to proceed with an action for the 
foreseeable future (at least 6 months), (b) The Contemplation Stage that is described as 
the period when people have an intention to take action within the next 6 months, (c) The 
Preparation Stage, which is characterized by the intent to take action in the near future 
(next 30 days), (d) The Action Stage, which is defined as the first six months of change 
implementation, and (e) The Maintenance Stage which involves the ongoing process of 
sustaining changes and preventing relapse.  Research regarding a range of behaviors has 
shown that the majority of individuals, typically about 80%, are in the precomtemplative 
and contemplative stages (Laforge, Velicer, Richmond, & Owen, 1999; Velicer, et al., 
1995).  Forced implementation of change during the contemplative and precontemplative 
stages may lead to poor outcomes.   Specifically, when organizational initiatives are not 
stage-matched, they can create reactions such as resistance and defensiveness from 
employees that are not ready for that level of change.  This common scenario has been 
cited as an important contributing factor in explaining why most organizational change 
initiatives fail (Levesque, Prochaska, & Prochaska, 1999). 
The concept of a decisional balance, which compares the pros and cons of change, 
was originally proposed by Janis and Mann (1977).  According to Prochaska and 
Diclemente (1983), the construct of decisional balance is likely an underlying factor that 
affects the level of intention that is classified by stage of change.  It is theorized that 
higher stages of change are characterized by a greater pro to con ratio; thus, 
Transtheoretical Model of Change programs seek to increase the pros of changing while 
decreasing the cons.  Additionally, another factor that appears to correlate with stage of 
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change is the concept of self-efficacy.  Bandura (1977) described self-efficacy as the 
degree to which people believed they had the capacity to attain a desired goal.  Self-
efficacy can influence an individual’s readiness for change by affecting their levels of 
motivation and persistence (Levesque, Prochaska, & Prochaska, 1999).  Moreover, higher 
levels of self-efficacy appear to promote durability of change and safeguard against 
relapse.               
Prochaska and Diclemente (1984) identified 10 fundamental patterns of activity 
that promote change readiness and action known as processes of change.  These 
processes of change include: consciousness raising, dramatic relief, self-reevaluation, 
self-liberation, environmental reevaluation, reinforcement management, counter-
conditioning, helping relationships, stimulus control, and social liberation.  Research 
suggests that people in earlier stages of change, such as precontemplative and 
contemplative levels, rely more on consciousness raising, dramatic relief, and 
environmental reevaluation processes (Prochaska, Diclemente, & Norcross, 1992).  
Individuals in the preparation stage are more influenced by self-evaluation and self-
liberation techniques, and persons who reached the action and maintenance phases relied 
more heavily on reinforcement management, helping relationships, counter-conditioning, 
and stimulus control processes in order to complete and sustain change.  Although the 
activities described above are part of the natural process that individuals may go through 
when considering change, these processes may also be used by change agents in order to 
encourage or elicit behaviors that promote a desired organizational change.  Levesque, 
Prochaska, and Prochaska (1999) proposed that interventions should be individualized by 
matching and the organizational members’ readiness to change with the indicated process 
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of change. For example, if the organization has determined that the majority of its 
members are in the contemplative and precontemplative stages of readiness for change, 
the organization might utilize consciousness raising techniques such as sending out 
newsletters or memos that can increase the awareness of the proposed change and its 
benefits.  By utilizing this type of stage-matched intervention, the researchers claimed 
that the organization can reduce resistance, stress, and time needed to implement a 
desired change by superficially accelerating the natural movement toward the action 
phase.  Conversely, they suggest that using a change process that is too advanced for the 
individual members’ readiness is likely to result in increased resistance and resentment.  
Thus, appropriately matching the stage and process of change is important in order to 
optimize the conditions for change and maximize the chances of implementing a 
successful and durable change within organizations. 
Diffusion of Innovation Model.  Innovations are ideas that are perceived as new 
and different, and diffusion is the process by which innovative ideas spread through a 
social system over time, via various communication channels (Rogers, 2004).  The 
Diffusion of Innovation Model was developed in the 1950s in response to agricultural 
research regarding the dissemination of knowledge and usage of new heartier and high 
yield hybrid corn seeds in Iowa (Rogers, 2004; Rogers, 2003; Ryan & Gross, 1943).  The 
Iowa hybrid seed corn study showed that earlier adopters of the innovative farming 
techniques shared some important characteristics.  These farmers were generally found to 
have larger farms, higher incomes, and more education.  Additionally, early adopters 
made more frequent trips to Des Moines, and they were more likely to have a neighbor 
who was using the hybrid seed method.  The findings from this and subsequent 
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agricultural research studies revealed an information-exchange process that was central to 
the diffusion of innovations.  Specifically, it was theorized that early adopting farmers 
had more opportunities for exposure to communication that could increase awareness and 
knowledge of potential benefits for using the new corn planting method.    
 Rogers (2004; 2003) continued the work related to studying agricultural diffusion 
for his dissertation in 1957.  However, as he encountered similarities in literature related 
to the process of implementing change in other types of systems such as schools, he 
became convinced that he had discovered a more generalizable model of change.  In 
1962, he introduced the idea of a general diffusion model in his book, Diffusion of 
Innovations.  To date, five subsequent editions of the book have been published, and 
research based on this model has been produced by marketing scholars, public health 
researchers, political scientists, and anthropologists.  
 According to Rogers (2003), decisions about whether or not an individual or 
organization will adopt a potential innovative practice is a process that occurs over time 
and can be understood as a series of stages. The first stage, knowledge, occurs when the 
decision making unit gains awareness of an innovation’s existence and an understanding 
of how it functions.  This may be preceded by the identification of a specific need that the 
innovation addresses, or exposure to the innovation may promote a desire to adopt it such 
as is common with consumer goods.  During the next stage, persuasion, a favorable or 
unfavorable impression regarding the innovation is formed.  This stage is characterized 
by active engagement and knowledge seeking in order to evaluate the innovation’s 
potential advantage, compatibility, and complexity for the potential adopter.  The third 
stage, decision, is characterized by engagement in activities that lead to a choice to adopt 
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or reject the innovation.  For example, the potential adopter may try the innovation on a 
partial or trial basis in order to facilitate this step in the process.  Implementation, the 
fourth stage, occurs when the system puts a new idea into action.  This is typically a 
tenuous part in the process since implementers generally continue to have apprehension 
about potential consequences at this stage.  Change agents may help to facilitate the 
implementation of innovations by offering information and technical assistance.  The 
final stage, confirmation, takes place when the decision making unit seeks reinforcement 
of the innovation-decision.  If exposed to conflicting messages about the innovation, the 
decision making unit may reverse the previous innovation-decision.  Additionally, it is 
important to note that each stage is a potential point for rejection or re-invention of the 
proposed innovation.  Re-invention, or modification of the innovation by adopters, is not 
necessarily a bad thing.  It can actually lead to beneficial customization and a greater 
sense of personal investment that may help to encourage a stakeholder mentality among 
individual group members.   
Although the Diffusion of Innovations Model was originally designed as a 
generalization about the spread of new ideas among individuals, it has also been adapted 
to serve as a template for innovating in organizations (Rogers, 2004).  As previously 
mentioned, an organization is a system of individuals who work together via prescribed 
roles, rules, and division of labor in order to achieve predetermined common goals 
(Roger, 2003).  Depending on the structure of the organization and the nature of the 
proposed new idea, innovation decisions fall into three categories: optional innovation-
decisions, collective innovation-decisions, and authority innovation-decisions.  An 
optional innovation-decision can be made by individuals within an organization 
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regardless of decisions made by other members.  A collective innovation-decision is 
made by a majority of a system, but compliance is mandatory for all members once the 
innovation is adopted.  An authority innovation-decision is made by relatively few high 
powered organization members, but it is mandatory for all organization members.   
 The innovation process for organizations also consists of five stages: agenda-
setting, matching, redefining/restructuring, clarifying, and routinizing (Rogers, 2003).  
The first stage, agenda-setting, is a constant process of defining and prioritizing problems 
that need to be addressed within an organization.  Matching, the second stage, happens 
when an innovation is identified that will be used to address the problem.  The next stage, 
redefining/restructuring, occurs when the innovative idea and the organization’s structure 
are both modified to ensure that there is a good fit between innovation and organization.  
The fourth stage, clarifying, allows members of an organization to construct their own 
meaning and understanding of the innovation through widespread implementation.  In the 
final stage, routinizing, the innovation loses its separate identity and becomes an accepted 
regular function of the organization.  
According to Rogers (2003), the innovation process for organizations is much 
more complex than that for individuals.  This is in part due to the sheer number of 
individuals within the larger system who may have an active role in the innovation-
decision and implementation processes.  Individuals who have earned and maintained a 
high degree of technical competence, social accessibility, and conformity to the system’s 
norms are more likely to be opinion leaders.  These persons are frequently able to 
influence the attitudes and behaviors of others by acting as social models or using well 
developed communication skills.  An individual that represents a change agency external 
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to the organization is known as a change agent. Change agents provide an important 
communication link between a resource system and a client system.  Examples of change 
agents are teachers, public health workers, agricultural extension agents, salespeople, and 
development workers.  Change agents seek to influence the client’s innovation-decisions 
toward the change agency’s desired outcome, and they often attempt to recruit opinion 
leaders to further their cause.  When a charismatic person within the organization 
endeavors to promote the adoption of new ideas they are referred to as an innovation 
champion.  Innovation champions contribute the likelihood of success of an innovation 
within the organizational setting by addressing indifference and resistance among their 
peers. 
Organizational change in community mental health settings.  There has been 
little research published specifically regarding the implementation of change in 
community mental health settings.  However, Schulz and Greenberg (1995) proposed one 
theory and framework for evaluating the implementation of change related to their 
innovative project aimed at the improvement of the quality of life for persons with severe 
and persistent mental illnesses.  They posited that environmental, organizational, and 
change agent characteristics are all forces that interact and influence change to varying 
extents.  Additionally, they suggested that these forces also interact with the innovation 
and change itself in a multidirectional manner.   
The environmental factors that are likely to impact the change process are the 
culture, stability, and structure of the environment (Schulz & Greenberg, 1995).  The 
broader culture in which a community mental health clinic is embedded influences the 
diagnosis, care, and acceptance of mental illness for the client population that the agency 
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serves.  The relative structure and stability within which an agency operates will also 
likely affect the likelihood of promoting or resisting change.  For example, a community 
that values formality and stability is more likely to resist change than one with informal 
structure that is used to implementing changes.  
Organizational aspects proposed to influence implementation of change are 
culture, stability, structure, resources, and interest groups (Schulz & Greenberg, 1995).  
The organizational culture, or the shared values and mission of an agency, is likely to 
impact the way that staff regard proposed changes to client care.  Additionally, the 
stability and structure of the organization can also impede or promote innovation.  The 
availability of agency resources such as travel and time for further training could be 
another factor that may influence the adoption or rejection of a proposed change within 
the community mental health setting.  Finally, Schulz and Greenberg (1995) also 
suggested that key interest groups such as unions or members of different professions 
were likely to have different perceptions of the change and its potential benefits and 
consequences.  Thus, these groups may either advocate for or resist change based on their 
unique perspectives. 
Schulz and Greenberg (1995) also proposed that change agents’ personal 
characteristics, influence and resources, strategies used, and manner of assisting the 
organization in implementing change are important in effecting successful change.  These 
authors asserted that personal characteristics like vision for the agency, motivation to 
affect change, and the ability to influence others are essential ingredients in promoting 
adoption of an innovation.  Another key consideration is the change agent’s ability to 
gain control over resources needed for the implementation of the proposed innovation; 
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therefore, support from the executive levels of an organization were found to be highly 
beneficial.  Additionally, it is important that the change agent has an implementation 
strategy that incorporated knowledge about the agency’s and the community’s cultural 
factors to decrease the chances of resistance and rejection of the change.  Some change 
agents may also influence the likelihood of successful adoption of innovations by 
assisting those in the organization who are responsible for directly implement those 
changes.    
  The above outlined theories of change and innovation have significant overlap; 
therefore, for the purposes of this dissertation project, they will be used in an integrative 
manner.  For example, Rogers (2003) asserted that his five stages of the innovation-
decision process can be thought to correspond directly to five phases in Prochaska and 
Diclemente’s (1983) stages of change model.  By utilizing information from both of these 
models, individualized stage-matched interventions can be identified and utilized in this 
translation research.  Additionally, Schulz and Greenberg’s (1995) framework will be 
used to add in considerations that are specific to the organizational structure and purpose 
of community mental health agencies.  
Overview     
 Although it is evident from the preceding literature review that there has been a 
considerable amount of research devoted to the exploration of effective treatments for 
panic disorders, it is also notable that there is a dearth of translational research regarding 
this topic.  Most research has been conducted in highly controlled settings with rigorously 
screened client populations; however, conditions are typically much more complex in real 
life settings such as community mental health agencies.  Furthermore, longitudinal 
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studies have shown that despite recommendations to the contrary, benzodiazepines 
continue to be prescribed more often than other pharmacological or behavioral treatment 
methods. Thus, there is a clear need for further translational research that takes into 
consideration factors related to implementing innovative best practice recommendations 
for treating panic disorder in organizations.   
This dissertation also explored the diffusion of innovations regarding the 
treatment of panic disorder in a community mental health agency. Specifically, this study 
captured a profile of current knowledge, skills, attitudes, and practices within a large 
metropolitan community mental health agency, and examined potential options and 
dilemmas involved in implementing innovative or best practice guidelines for the 
treatment of panic disorder.  The project utilized methods including database analysis and 
record review to formulate an accurate profile of the agency’s current treatment practices.  
Additionally, a survey of key personnel that influence client care was used to generate 
information that provided information regarding the organization’s view of the potential 
need for innovative panic disorder treatment practices and possible obstacles or 
impediments for implementing changes in treatment standards.  The results of this 
investigation are discussed in light of organizational change literature and what current 
results imply regarding successful treatment strategies for panic disorder in a community 
mental health setting.  The findings from this study also were used to produce a report for 
the participating agency that included a detailed summary of their current panic disorder 
treatment practices and a clear profile of knowledge, skills, and attitudes regarding the 
management of panic disorders held by different key agency sub-groups.  These findings 
also are compared to the existing literature base on organizational change in community 
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mental health systems to generate possible implications for future action and 
recommendations.  
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Methods 
In order to capture a profile of the knowledge, skills, attitudes, and practices 
within a large metropolitan community mental health agency, and examine potential 
options and dilemmas involved in implementing innovative or best practice guidelines for 
the treatment of panic disorder, this project utilized two types of information gathering 
techniques. The first method included a survey of client care providers at the participating 
agency, and the second involved a database analysis of client demographic and outcome 
figures. The methods and participants of these information gathering strategies are 
explained below.   
Phase One Method: Panic Disorder Treatment Survey 
First, an online survey (Appendix A) was designed and administered to key 
personnel that influence client care. The survey was used to provide an overview of the 
knowledge, skills, and attitudes of treatment providers at the participating agency. 
Additionally, it generated information regarding the organization’s view of the potential 
need for innovative panic disorder treatment practices and possible obstacles or 
impediments for implementing changes in treatment standards. 
Participants.  In total, 46 client care personnel and administrators completed the 
survey.  The total number of administration and client care employees available to take 
the survey was 170; thus, a response rate of 27% was achieved. The majority of 
participants (78%) were female (36 females, eight males, and two undisclosed).  
Similarly, the agency reported that majority of the employees (85%) at their agency that
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were eligible to complete the survey were female (145 females and 25 males).  Age was 
reported via response to a multiple choice question with 10 year increments on the 
survey, and participants’ reported ages ranged from 20s to 60s.  Slightly greater than a 
third of the respondents indicated their age was in the 31-40 years old age range (n=16). 
However, the rest of the participants were relatively evenly distributed among the 21-30 
(n=9), 41-50 (n=5), 51-60 (n=11), and 61-70 (n=5) age ranges.  It appears that the ages of 
survey participants was a good representation of client care population at the participating 
agency which was also relatively evenly distributed among the 21-30 (n=39), 31-40 
(n=47), 41-50 (n=38), 51-60 (n=30), and 61-70 (n=16) year age ranges.   
Approximately 61% (n=28) of the respondents indicated their highest completed 
educational degree as a master’s degree compared to 55% (n=94) of the total client care 
population that the participating agency. The remaining participants indicated educational 
attainment levels of associates, bachelors, and doctorate degrees, and each of these 
degreed groups represented 13% (n=6) of the total participants surveyed.  Likewise, the 
agency reported a much lower number of employees with highest educational attainment 
levels of associates (n=30), bachelors (n=32), and doctorate (n=14) degrees than master’s 
degree employees (n=94).  The sample consisted of respondents from disciplines 
including counseling (n=19), social work (n=13), nursing (n=7), psychology (n=6), and 
medicine (n=4). Two participants indicated “other” as their professional discipline (see 
Figure 1). This number is identical to that of respondents indicating that their practice 
area was administration without client care; therefore, these respondents are likely 
professionals from disciplines related to business operations.  The agency also provided 
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similar data on the number of staff by discipline for counseling (n=80), social work 
(n=52), nursing (n=10), psychology (n=9), psychiatry (n=10), and administration (n=9). 
Overall, the demographic data provided by the survey respondents indicated that a 
representative sample of the key personnel that influence client care at the participating 
agency had been reached. Thus, data collected from survey questions regarding 
knowledge, attitudes, skills, and practice should be useful for in creating an overall 
agency profile, and also for examining similarities and differences between subgroups of 
client care personnel such as by discipline, practice area, sex, or educational level of 
agency employee.   
Instrument.  The online survey was designed and administered utilizing the 
SurveyMonkey web-service.  The survey was a 50-item instrument that included 
questions with yes/no, multiple choice, and 4 point Likert type answers. The instrument 
included questions regarding demographic information such as age, sex, gender, 
educational level, and clinical practice area. Additionally, the survey asked participants to 
indicate their level of training and clinical experience with treating individuals with panic 
disorder. Additionally, client care personnel were asked to provide their opinions about 
the level of safety and effectiveness for different types and combinations of therapy and 
pharmacological interventions for panic disorder.  Specifically, the therapy treatment 
modalities rated included behavioral exposure, cognitive behavioral therapy, panic 
focused psychodynamic psychotherapy, and emotion-focus psychotherapy for panic 
disorder. The psychopharmacological interventions considered were antidepressants 
(Prozac, Lexapro, Effexor, etc.) and benzodiazepines (Xanax, Ativan, Klonopin, etc.).    
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The survey instrument also included a section that explored knowledge and 
attitudes regarding the nature, course, prognosis, and treatment considerations for 
individuals with panic disorder. In this section, the participants were asked to rate their 
own level of knowledge and training related to treating clients with panic disorder as well 
as agency practices of referral and treatment.  The respondents were also asked to 
indicate their agreement with statements concerning likelihood of client motivation, 
compliance, and relapse in response to different treatments.  Moreover, these items 
explored attitudes and knowledge regarding potential treatment issues related to tolerance 
for psychotherapeutic intervention and drug dependence or abuse.  
Procedure.  The participating agency asked its client care employees to complete 
the online survey. Administration and department managers utilized a script that was 
designed by the researcher and agency officials (and approved by the agency’s quality 
department and the researcher’s university) to explain the survey portion of this research 
through emails and department meetings. This script can be found in Appendix B. The 
web address and hyperlink to the survey was provided in the email sent out to all eligible 
client care employees. The agency personnel were allowed to complete the survey over a 
1- month time span at their convenience on any available computer.  The agency’s 
administrators and managers decided to encourage all of their employees to participate in 
the survey so that they could gain information about panic disorder treatment opinions 
and practices among their employees. Thus, an incentive was offered in the way of a 
drawing for one of four $50.00 Amazon.com gift cards. The survey included an item 
allowing employees to voluntarily consent or refuse the use of their survey answers for 
this research and potential publication. The survey responses were then filtered by the 
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answer to the consent item, and only those respondents that consented to have their 
answers used for research were used for this dissertation project. Thus, the 46 participants 
of this research project refers to the individuals that agreed to allow their answers to be 
used for research and publication purposes from the total 52 survey respondents. As an 
incentive for participation in this research project, individuals were given the ability to 
follow a hyperlink that was embedded in the online survey in order to register for a 
chance at one of four $50 gift certificates. These certificates were awarded to individuals 
through a random drawing.  
Data Analysis.  After the responses were collected and filtered by consent to 
participate in this research project, the resulting data were downloaded and analyzed 
using the NCSS, 2007 Edition statistical software.  Additionally, charts and tables were 
constructed utilizing Microsoft Excel tools.  Both one-way analysis of variance 
(ANOVA) and goodness-of-fit (chi-squared) statistical analysis were used to summarize 
findings and describe the relationships between demographic variables and knowledge, 
attitude, skills, and practices.        
Phase Two Method: Database Review    
This project also utilized a database analysis of client diagnostic, treatment 
modalities and duration, as well as pre and post functional ability scores to formulate an 
accurate profile of the agency’s current treatment practices and outcomes.  A formal plan 
(Appendix C) for collecting and aggregating this information from client electronic 
charting records was devised with a representative from the agency’s quality department 
and approved by the participating agency and the researcher’s university for this 
 
42 
 
dissertation project.  The resulting summary data were used to gain a better understanding 
of current panic disorder treatment practices.  
Participants.  The total number of active and terminated cases reviewed for 
possible inclusion in this database summary was 7,828 (active n=3,884; terminated 
n=3,944). The time period sampled included 3 years prior to the current study.  In order 
to decrease the number of diagnostic and treatment variables considered for this project, 
only client records with panic disorder only (with or without agoraphobia) were included 
in the database review for this project. Of those potential cases, 248 records showed a 
diagnosis of panic disorder and 139 records indicated a diagnosis of only panic disorder. 
It is the practice standard of the participating agency not to provide medication services 
to clients who are not concurrently enrolled in therapy.  Therefore, the treatment 
conditions that were identified were therapy only and therapy with benzodiazepine 
medication services.  Of the panic disorder only cases, 19 received therapy only, while 
119 received a combination of benzodiazepine medication and therapy.  This sample was 
further refined to include only clients who had terminated during the 3-year time period 
reviewed in order to assess treatment outcomes such as differences in pre and post GAF 
scores and duration of treatment in months.  The total number of participants in the 
therapy and benzodiazepine medication group was 20, while only five cases received 
therapy alone for panic disorder.  
Procedure.  Three years of client electronic charting information was sanitized of 
identifying information and compiled into summary reports according to treatment 
modality. In order to create a data summary that could be compared to current best 
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practice standards, the diagnostic and treatment variables outline above were used to 
refine the database search.   
Data Analysis.  After the database summary was compiled and sanitized of 
patient identifying information by the agency representative, the resulting data were 
analyzed by again utilizing NCSS, 2007 Edition statistical software.  Descriptive 
statistical analysis was completed to summarize and compare diagnostic and treatment 
information with outcomes and duration of treatment.  The findings of this database 
review were compared to literature regarding best practices to generate inferences about 
effectiveness of the agency’s current practices and produce recommendations for 
potential future directions.      
In sum, the methods outlined above were designed to capture an accurate profile 
of the knowledge, skills, attitudes, and practices related to the treatment of individuals 
with panic disorder at the participating agency.  However, the collection of data in this 
project was meant to represent a “case in point,” and the information gathered from the 
participating agency was compared with existing research about best practices for 
treating panic disorder. Furthermore, classic organizational change literature and research 
regarding program change within community mental health organizations was helpful in 
formulating inferences about and implications of the data collected in this project. 
Finally, it is the researcher and participating agency’s wish that the findings produced by 
the extensive methods outlined above will contribute to the current dearth of translational 
research regarding panic disorder treatment and outcomes in a real world clinical setting.    
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Results 
The data resulting from the two phases of investigation in this study were 
analyzed with the use of NCSS statistical software in order to test the significance of 
findings for the key variables of interest.  For the purposes of this study, differences were 
determined to be significant if they reached the .05 level of significance (p < .05).  In the 
first phase of this study, the agency survey on panic disorder treatment knowledge, skills, 
and attitudes, was analyzed to determine the presence of any significant differences 
among client care cohorts. A chi-squared (χ
2
) goodness of fit test was performed on the 
categorical data collected from the survey, and one-way analysis of variance (ANOVA) 
was used for the Likert scored data.  A Tukey-Kramer post-hoc test was also utilized 
during analysis in order to adjust for potential sources of error such as unobservable 
latent variables when examining variance between groups.  This step was useful in 
describing the direction and strength of the relationships between the multiple variables 
being analyzed in this study.  Additionally, tables and figures such as box plot graphs 
with indicated means, ranges, and outliers, were utilized to visually represent results.  
Cohorts that were examined in this study included groups that varied by discipline, 
highest educational level, age, and reported extent of panic disorder specific training.  
The second phase of investigation included the collection of client treatment data, 
which were analyzed for differences between pre- and post-treatment among clients 
receiving therapy alone and those receiving a combination of therapy and benzodiazepine
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medication for the treatment of panic disorder.  Pairwise differences for these two 
treatment groups were analyzed using t-tests.    
Phase One Results: Panic Disorder Treatment Survey 
During the initial analysis of the survey responses, the overall results were 
considered to identify areas of participant agreement and potential themes (Appendix D).  
For example, the majority of participants surveyed indicated that they had received 
training in treating panic disorder through readings (n=32, 71.1%), coursework (n=28, 
62.2%), and supervision (n=23, 51.1%), while slightly fewer had participated in training 
workshops (n=22, 48.9%) on the topic.  There was also considerable agreement among 
participants about the percentage of clients from their case loads that had only a diagnosis 
of panic disorder, with the majority indicating that only 0-5% (n=29, 65.9%) or 5-10% 
(n=6, 13.6%) of their clients fit that description. Additionally, most respondents indicated 
some level of agreement (a combination of strongly agree and somewhat agree figures 
responses) that they felt they had enough knowledge/training about panic disorder 
treatment (n=39, 84.7%), and they thought their own and the agency’s practices were safe 
and effective (n=41, 93.2% and n=42, 93.3% respectively).  The majority of participants 
(n=36, 78.3%) also indicated agreement with the following statement: “clients presenting 
with panic disorder should be referred for psychotherapy before being referred for 
medication.” 
Overall results of items that asked about the safety and effectiveness of different 
therapy treatment approaches for panic disorder revealed several areas of general 
consensus among participants. When asked which therapy approach was safest and most 
effective, most participants chose cognitive-behavioral therapy (n=23, 79.3% and n=18, 
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60% respectively). The majority of participants also indicated that cognitive-behavioral 
therapy was the most similar therapy approach to their own (n=25, 83.3%) and the one 
with which they had the most training and experience (n=25, 83.3%).  Most participants 
were least familiar with panic focused psychodynamic psychotherapy (n=23, 76.7%).  
The majority of respondents indicated they thought panic focused psychotherapy (n=13, 
46.4%) and emotion-focused psychotherapy for panic disorder (n=11, 39.3%) were the 
least effective therapy approaches. However, behavioral therapy (n=12, 46.2%) was 
selected by more participants as the least safe approach, compared to panic focused 
psychotherapy (n=10, 38.5%) and emotion-focused psychotherapy for panic disorder 
(n=4, 15.4%).  
There was also agreement found among many of the participants for items 
regarding medication treatment for panic disorder.  For example, most survey 
respondents indicated that they thought antidepressants (n=31, 81.1%) were the safest 
medication for treating the panic disorder, and benzodiazepines (n=33, 86.8%) were the 
least safe medication treatment. Additionally, more respondents chose antidepressants 
(n= 17, 45.9%) over benzodiazepines (n=11, 29.7%) as the most effective medication for 
treating panic disorder. Most respondents also indicated agreement (strongly agree and 
somewhat agree response figures collapsed) with the following statements about potential 
issues with benzodiazepine prescriptions: “benzodiazepines build dependency” (n=42, 
91.3%); “some clients may abuse or sell their benzodiazepine prescription medications” 
(n=43, 93.4%); and “clients prescribed benzodiazepine medications for their panic 
disorder, may not attend psychotherapy appointments regularly” (n=35, 76.1%).  
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On survey items about combination therapy and medication approaches, 
participants were asked to consider treatment options including therapy alone, medication 
alone, a combination of therapy and benzodiazepine medication, and a combination of 
therapy and antidepressant medication. Most participants favored antidepressant 
medication with therapy for the treatment of panic disorder in regards to safety (n=30, 
78.9%) and effectiveness (n=22, 57.9%).  Medication alone was indicated as the least 
safe (n=24, 63.2%) and least effective (n=23, 60.5%) of the approaches outlined.  
However, many items that did not yield a consensus opinion, and examination of 
the overall results leads to a hypothesis that differences may exist between specific 
participant cohort groups. Thus, further statistical analysis of the responses collected 
from the 46 client care and administrative personnel participants who completed the 
panic disorder treatment survey focused mainly on identifying differences between 
cohorts in answering questions regarding knowledge, skills and attitudes on the treatment 
of panic disorder. Participant cohorts that were explored in this study were defined by 
variables including highest educational level attainment, discipline, practice area, and 
types of professional training they had received in treating panic disorder.   
Discipline.  The first cohort variable was that of professional discipline.  The 
survey respondents included 10 social workers, 18 counselors, seven nurses, four 
psychiatrists, and five psychologists. Two participants could not be included in the 
analysis by discipline because they chose not to answer this survey item.  Due to the 
small number of participants who identified as nurses and psychiatrists, these respondents 
were collapsed into a single discipline variable that will be referred to as “medical” in 
order to improve the statistical accuracy of analysis.  Combining these groups of 
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respondents makes sense since the psychiatric nurses at this agency work closely with the 
psychiatrists surveyed and their job duties include monitoring, and in the case of the 
nurse practitioners, prescribing psychotropic medications.  When survey responses were 
analyzed by discipline, several significant findings emerged.  The breakdown of 
respondents by discipline is shown in the Figure 1: 
 
 
Figure 1. Percentages of Participants by Discipline. 
 
For survey items regarding the perceived safety and effectiveness of different 
types of treatment for panic disorder there were two significant finding of difference 
among the discipline groups identified. For example, the one-way analysis of variance 
(ANOVA) comparing discipline with judged safety and effectiveness of antidepressant 
medications for the treatment of panic disorder, showed  significant differences between 
disciplines, F(3,32) = 2.93, p =.048.  A Tukey-Kramer post-hoc comparison of the four 
groups showed that the psychologists (M = 2.4) indicated significantly less agreement 
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with the survey item positing the safety and effectiveness of antidepressant medications 
for the treatment of panic disorder, than the counseling and medical groups respectively 
(Ms =1.67 and 1.4).  The result of this first analysis appears in the Table 1 and Figure 2: 
 
Table 1  
Statistical Analysis of Responses to Item: Regarding the treatment of panic disorder, I 
believe antidepressant medications are safe and effective.   
 
Analysis of Variance  
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
3.372 
12.267 
15.639 
3 
32 
35 
1.124 
0.383 
----- 
2.93 
----- 
----- 
0.048 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Social Worker 6 1.667 ----- 
Counseling 15 1.667 ----- 
Medicine 10 1.4 Psychologist 
Psychologist 5 2.4 Medicine 
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Figure 2.  Response to item: “Regarding the treatment of panic disorder, I believe 
antidepressant medications are safe and effective.”   
 
Turning to the next tabled analysis shown in Table 2 and Figure 3,  one can see 
that there was also a significant difference in agreement among disciplines on the  survey 
item stating that therapy alone is a safe and effective treatment for panic disorder, F(3, 
32), p = .017.  On this item, Tukey-Kramer post-hoc analysis revealed that the 
psychologist group (M = 1.2) indicated a significantly higher level of agreement than the 
social workers, counselors, and medical groups respectively (Ms = 2.127, 2.4, and 2.3).  
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Table 2 
Statistical Analysis of Responses to Item:  Regarding the treatment of panic disorder, I 
believe therapy alone is safe and effective.   
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
5.667 
15.333 
3 
32 
35 
1.889 
0.479 
----- 
3.94 
----- 
----- 
0.017 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Social Worker 6 2.167 ----- 
Counseling 15 2.4 Psychologist 
Medicine 10 2.3 Psychologist 
Psychologist 5 1.2 Counseling, Medical 
 
 
Figure 3.  Responses to item:  Regarding the treatment of panic disorder, I believe 
therapy alone is safe and effective.   
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 In a somewhat related item, discipline was associated with a highly significant 
degree of difference, F(3. 32), p = .005,  regarding the statement: “When psychotherapy 
has been effective for patients with panic, they will not tend to relapse.”  Again, post hoc 
analysis revealed that the variance was accounted for by differences between the 
psychologist group (M = 1.8) and the medical and social worker groups (Ms = 2.727 and 
2.9).   
 
Table 3  
Statistical Analysis of Responses to Item: When psychotherapy has been effective for 
patients with panic, they will not tend to relapse. 
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
5.118 
13.882 
19 
3 
40 
43 
1.706 
0.347 
4.92 
----- 
----- 
0.005 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Social Worker 10 2.9 Psychologist 
Counseling 18 2.333 ----- 
Medicine 11 2.727 Psychologist 
Psychologist 5 1.8 Social Worker, Medicine 
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Figure 4. Responses to Item: When psychotherapy has been effective for patients with 
panic, they will not tend to relapse. 
 
As seen in the next results table, analysis of the level of agreement among 
discipline cohorts with another statement:  “Benzodiazepine medications interfere with 
successful psychotherapy,” also demonstrated a highly significant level of difference, 
F(3.32), p = .008 among disciplines.  Post-hoc analysis showed that the psychologist 
group (M = 1.4) indicated a significantly greater level of agreement with that statement 
than did the social worker, medical, and counseling groups (Ms = 2.8, 2.727, 2.667).   
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Table 4  
Statistical Analysis of Responses to Item Stating: Benzodiazepine medications interfere 
with successful psychotherapy. 
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
7.814 
22.982 
30.795 
3 
40 
43 
2.605 
0.575 
4.53 
----- 
----- 
0.851 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Social Worker 10 2.8 Psychologist 
Counseling 18 2.667 Psychologist 
Medicine 11 2.727 Psychologist 
Psychologist 5 1.4 Social Worker,  
Counseling, 
Medicine 
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Figure 5. Responses to Item Stating: Benzodiazepine Medications interfere with 
successful psychotherapy. 
 
Regarding the statement: “Clients prescribed benzodiazepine medications for their 
panic disorder may not attend psychotherapy appointments regularly,” a one-way 
analysis of variance revealed another significant difference among discipline groups, F(3, 
32), p = .038. The Tukey-Kramer’s post-hoc analysis of this item revealed that the 
significant variance was accounted for between the psychologists (M = 1.2), who 
indicated a much higher level of agreement with that statement, and the social worker 
group (M = 2.4) who did not indicate as much agreement with it.  
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Table 5  
Statistical Analysis of Responses to Item Stating: Clients prescribed benzodiazepine 
medication for their panic disorder may not attend psychotherapy appointments 
regularly.  
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
5.414 
23.382 
28.795 
3 
40 
43 
1.805 
0.585 
3.09 
----- 
----- 
0.678 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Social Worker 10 2.4 Psychologist 
Counseling 18 2 ----- 
Medicine 11 1.727 ----- 
Psychologist 5 1.2 Social Worker 
 
Figure 6. Responses to Item Stating: Clients prescribed benzodiazepine medication for 
their panic disorder may not attend Psychotherapy appointments regularly.  
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Turning from the Likert scaled items to the categorical response items, the results 
of the chi-square test of goodness-of-fit analysis on the question of whether the 
participants thought either benzodiazepines or antidepressants were safer for treating 
panic disorder appears below. Ratings for safety for the two medications were not equally 
distributed in the population, χ
2
 (6, N = 36) = 13.543, p = .035, and there appears to a 
significant relationship between discipline and perceived safety of different classes of 
medications. While most participants (87%) from the social worker, counseling, and 
medical disciplines appeared to favor antidepressant medications in regards to safety, 
over half (60%) of the participants from the psychologist group endorsed neither 
medication as the safest approach for treating panic disorder. 
 
 
Figure 7.  Responses to Item: Regarding the treatment of panic disorder, I believe the 
following medications are safe and effective.  
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In another item that was analyzed using the chi-squared test, participants were 
asked to indicate which therapy approach they thought was safest: behavioral therapy, 
cognitive-behavioral therapy, panic focused psychodynamic psychotherapy, or emotion 
focused therapy. Participants’ endorsements for safest therapy was not equally distributed 
among disciplines, χ
2
 (9, N = 29) = 17.068, p = .047, and there appears to a significant 
relationship between discipline and perceived safety of different therapy approaches.  
Specifically, although the majority of participants from the social worker (83%), 
counseling (75%), and psychology (100%) groups endorsed cognitive-behavioral therapy 
as the most safe and effective therapy approach, half (50%) of the respondents from the 
medical group favored panic focused psychodynamic psychotherapy. 
 
 
Figure 8.  Response to item: “Regarding the treatment of panic disorder, I believe the 
following therapies are safe and effective.”  
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Two other items that resulted in significant chi-square results involved familiarity 
with different combinations of medications and therapy for the treatment of panic 
disorder. Potential responses included therapy only, medication only, therapy and 
benzodiazepine, therapy and antidepressant, all of the above, or none of the above.  The 
first item that indicated a highly significant level of difference, χ
2
 (15, N = 36) = 34.269, 
p = .003, among discipline cohorts, asked participants to indicate the approach with 
which they were most familiar.  Most disciplines appeared to be most familiar with 
therapy and medication or all of the combination treatments, while the majority of the 
psychologist group cohort was most familiar with a therapy only approach to treating 
panic disorder.   
 
 
Figure 91.  Responses to the Item: With which of these approaches are you most 
familiar? 
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The item regarding the least familiar combination of treatments offered the same 
potential responses, and a goodness-of-fit test was also highly significant, χ
2
 (15, N = 36) 
= 33.527, p = .004.  On this item the medical cohort group appears to differ most from 
the other disciplines.  The medicine group indicated least familiarity with the therapy 
only approach, while the psychology and counseling groups appeared to be the least 
familiar with a medication only approach.  
 
 
Figure 2.  Responses to the Item: With which of these combined approaches are you least 
familiar? 
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educational level.  Survey participants were asked to indicate their highest level of 
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completed a doctoral degree.  When the data for survey participants was analyzed by 
cohorts, several significant differences in reported knowledge skills, and attitudes 
emerged.  The distribution of participants is presented in the Figure 11: 
 
 
Figure 3.  Percentages of participants by highest earned educational degree.  
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confidence in panic focused psychodynamic and emotion-focused psychotherapies, 
responses from the master’s degree group also indicated doubts about the effectiveness of 
behavioral therapy. The bachelor’s degree cohort responses were evenly distributed 
between cognitive-behavioral and emotion-focused therapy approaches.  
 
 
Figure 4. Responses for the item regarding the least effective therapy approach for the 
treatment of panic disorder.   
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safe therapy approach, and answers from the doctorate level respondents were split 
evenly among emotion-focused psychotherapy, panic focused psychodynamic 
psychotherapy, and behavioral therapy approaches.    
 
 
Figure 53.  Responses to the item regarding the least safe therapy approach for the 
treatment of panic disorder. 
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antidepressant medications for the treatment of panic disorder, than the associate’s, 
master’s, and doctorate degree groups respectively (Ms = 1.5, 1.68 and 1.67).  The result 
of this first analysis appears in the Table 6 and Figure 14. 
 
Table 6 
Statistical Analysis of Responses to Item Regarding the Perceived Safety and 
Effectiveness of Antidepressant Medications for Panic Disorder 
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
4.447 
12.106 
16.553 
3 
34 
37 
1.482 
0.356 
4.16 
----- 
----- 
0.013 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Associate 6 1.5 ----- 
Bachelor 4 2.5 Doctorate 
Master 22 1.682 ----- 
Doctorate 6 1.167 Bachelor 
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Figure 14.  Educational Cohort responses for survey item stating antidepressants are safe 
and effective for the treatment of panic disorder.  
 
A one-way analysis of variance (ANOVA) also revealed a significant difference, 
F(3,34), p = .02, among educational groups in their level of agreement with the statement: 
“Medication alone is a safe and effective treatment for panic disorder.”  The Tukey-
Kramer post-hoc comparison indicated that the doctorate group (M = 2.33) indicated a 
significantly higher level of agreement with this item than the master’s degree cohort (M 
= 3.27).  The difference between the bachelor (M = 3) and associate (M = 2.67) level 
cohorts was not significant.  The result of this analysis is presented in Table 7 and Figure 
15.  
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Table 7 
Statistical Analysis of Responses to Item Stating: Medication Alone Is a Safe and 
Effective Treatment for Panic Disorder 
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
4.967 
15.030 
3 
34 
37 
1.657 
0.442 
3.75 
----- 
----- 
0.020 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Associate 6 2.667 ----- 
Bachelor 4 3 ----- 
Master 22 3.273 Doctorate 
Doctorate 6 2.333 Master 
 
 
Figure 6.  Educational cohort responses for survey item stating medication alone is a safe 
and effective treatment for panic disorder.  
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Regarding the statement: “I feel that I have the knowledge/training to effectively 
help clients with panic disorder,” a one-way analysis of variance revealed another 
significant difference among educational level groups, F(3,42), p = .024. The Tukey-
Kramer’s post-hoc analysis of this item revealed that the doctorate and master’s level 
groups (Ms = 1.5 and 1.82 respectively) indicated a significantly higher level of 
agreement with the survey item, than bachelor’s and associate’s degree groups (Ms = 
2.67 and 2 respectively).  
 
Table 8 
Statistical Analysis of Responses to the Item Stating: I feel that I have the 
knowledge/training to effectively help clients with panic disorder 
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
4.712 
18.940 
23.652 
3 
42 
45 
1.571 
0.451 
3.48 
----- 
----- 
0.240 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Associate 6 2 ----- 
Bachelor 6 2.667 Master, Doctorate 
Master 28 1.821 Bachelor 
Doctorate 6 1.5 Bachelor 
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Figure 7.  Responses to Item Stating “I feel that I have the knowledge/training to 
effectively help clients with panic disorder.” 
 
As seen in the Table 9 and Figure 17, one-way analysis (ANOVA) of the level of 
agreement among educational level cohorts with another statement:  “Our center needs to 
revise its approach to treating panic disorder,” also demonstrated a significant level of 
difference, F(3,41), p = .021.  Post-hoc analysis (Tukey-Kramer’s Test) showed that the 
bachelor’s degree group (M = 1.833) indicated a significantly greater level of agreement 
with that statement than did the doctorate, master’s or associate’s degree cohorts, (Ms = 
2.33, 2.74, 3.167). 
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Table 9 
Statistical Analysis of Responses to Item Stating: Our center needs to revise its approach 
to treating panic disorder 
 
Analysis of Variance Table 
 
Sum of 
Squares 
 
Df 
Mean 
Square 
 
F-Ratio 
Probability 
Level 
Between 
Within 
Total 
6.392 
24.185 
30.578 
3 
41 
44 
2.131 
0.590 
3.61 
----- 
----- 
0.021 
----- 
----- 
 
Tukey-Kramer Multiple-Comparison Test 
Group Count Mean Different from Groups 
Associate 6 3.167 Bachelor 
Bachelor 6 1.833 Associate 
Master 27 2.741 ----- 
Doctorate 6 2.333 ----- 
 
 
Figure 8.  Responses for survey item stating, “Our center needs to revise its approach to 
treating panic disorder.” 
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There were no other significant differences found across the remaining items in 
relation to discipline or educational level.  Although one-way analysis of variance 
(ANOVA) and goodness-of-fit tests (chi-squared) were also used to examine potential 
differences related to extent of panic disorder specific training and age of participant, 
there were no other significant findings for the survey data analyzed.  
Phase Two Results: Database Review 
The second phase of this study involved analyzing a 3-year sample of client 
outcomes and duration data that was provided by the participating agency.  Although the 
parameters of this database review were narrowed to only include clients with “pure” 
panic disorder (with or without agoraphobia) diagnoses, the agency was able to provide 
figures on 138 records of applicable clients.  The treatment conditions that were 
identified in order to analyze the client outcome and duration were therapy only and 
therapy with medication services.  Of the panic disorder only cases, 19 received therapy 
only, while 119 received a combination of medication and therapy.  Since an admission 
and termination date are requisite in order to calculate duration, and the participating 
agency records GAF scores only at initial assessment and termination, only data from 
clients who had terminated treatment during the three year sampling period could be used 
for this analysis (n = 25).  Although the sample was collected from a 3-year period, the 
total number of clients that met the criteria of panic disorder only was very small. 
Additionally, only five of the clients included in the sample were in the therapy only 
treatment group, and 20 received therapy and benzodiazepine medication for the 
treatment of panic disorder. These small subsample groups mean that this study has low 
statistical power, and a type II error, or failure to detect differences when they exist, is 
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more likely to occur (Cleophas, Zwinderman, Cleophas, Cleophas, & Cleophas-Allers, 
2012). This limitation should be remembered when considering the results from the 
database review analysis.  
 Outcomes.  Client GAF scores for the two treatment groups.  Admission GAF 
scores ranged from 36 to 53 with a mean of 50.6, and termination scores had a range of 
43 to 60 with a mean of 58.04. An independent-samples t-test was used to analyze for 
difference in pre and post GAF scores for the two treatment groups described above.  The 
results of this analysis showed no significant difference in the scores for the therapy and 
benzodiazepine medication (M = 7.55, SD = 2.31) and the therapy only (M = 7, SD = 
1.87) treatment group conditions; t(23) = -0.492, p = .627.  The result of this analysis is 
presented in the Figure 18. 
 
Figure 9.  Comparison of change in GAF scores for therapy only and medication and 
therapy treatment groups.  
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Duration.  The other variable from the client record database that was analyzed 
for difference between treatment groups was duration. Treatment duration was measured 
in months, and the 25 cases used for comparison ranged from 5 to 37 months with a mean 
treatment period of 27.88 months.  An independent-samples t-test was used to analyze for 
difference in treatment duration between the therapy only and therapy and medication 
treatment groups.  The results of this analysis showed a highly significant difference in 
the duration of treatment between groups t(23) = -2.518, p =.019.  Specifically, the 
therapy and medication group (M = 29.95, SD = 6.72) had a significantly longer 
treatment duration, than the therapy only (M = 19.6, SD = 13.20) treatment condition.  
This result is presented in Figure 19.   
 
 
Figure 19.  Comparison of duration of treatment for therapy alone versus therapy and 
medication groups.  
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Discussion 
This study of knowledge, skills, attitudes, and current practices within a large 
community mental health agency was a case in point.  The purpose was to examine the 
potential options and dilemmas involved in implementing innovative or best practice 
guidelines for the treatment of panic disorder.  An accurate appraisal of current treatment 
practices was accomplished through record review and data analysis.  Additionally, a 
computerized survey with Likert type scaled items along with some categorical items was 
administered to key subgroups that influence client care in order to generate further data 
about organizational members’ knowledge, skills, and attitudes regarding the treatment of 
panic disorder.  Those findings were also used to generate information regarding the 
organization’s climate of change, readiness, and potential change process issues 
(Bouckenooghe, Devos, & Van Den Broeck, 2009).  Specifically, individual and systemic 
perceptions of the potential need for innovative panic disorder treatment practices and 
possible obstacles or impediments for implementing changes in treatment standards were 
identified.  The data generated from the record review and survey were reviewed in 
relation to the three research questions that were formulated at the outset of this study 
which included the following:  a) To what extent are there differences in current 
recommendations, reported practices, and reported knowledge or skills for the treatment 
of panic disorder at the community mental health agency being studied?  b) To what 
extent are there differences between or within agency cohorts relative to their knowledge, 
practices, and attitudes regarding the treatment of panic disorder?  c) To what extent are 
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treatment outcome variables related to the type of panic disorder treatment that clients 
receive?   
Phase One Discussion:  Panic Disorder Treatment Survey 
The panic disorder treatment survey was a computerized questionnaire about 
knowledge, skills, attitudes, and practices that was given to direct client care and their 
administrators at the participating agency.  Survey responses were analyzed for themes of 
overall agreement and between cohort differences.  Several significant differences were 
found between participant cohorts that were grouped according to demographic variables 
including educational attainment and discipline.  The discussion of this study’s findings 
are presented below in reference to items regarding medication for the treatment of panic 
disorder, therapy approaches, and general opinions items.    
Medications.  For items regarding the treatment of panic disorder with 
medications there were several items on which most survey respondents agreed.  For 
example, the majority of participants indicated that they thought antidepressants (n=31, 
81.1%) were the safest medication treatment option for treating panic disorder.  The 
participants confidence in the safety of antidepressants is in accord with research that 
shows that antidepressants are clinically efficacious in reducing the number and severity 
of reported panic attacks, while having the benefit of offering pharmacological coverage 
for symptoms associated with mood disorder comorbidities and presenting limited 
concerns about dependency or liability for abuse (American Psychiatric Association, 
2009; Pollack, 2006).  However, it should also be noted that research indicates that 
antidepressants can result in several bothersome side effects (Physician’s Desk 
Reference, 2007; Pollack, 2006).  Additionally, since side effects are most likely to occur 
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during the first few weeks of treatment, dosage is usually started at a lower rate and 
gradually titrated up to the therapeutic level.  These medications commonly take 6 to 8 
weeks to reach effectiveness; thus, there may be a prolonged period before clients can 
expect symptom reduction from antidepressants.  If clients choose to discontinue 
antidepressant treatments prematurely due to side effects or impatience, a discontinuation 
syndrome and return of the panic attack is likely to result (American Psychiatric 
Association, 2009; Shelton, 2006; Schatzberg, Blier, Delgado, Fava, Haddad, & Shelton, 
2006).  However, the biggest safety concern related to the use of antidepressants is 
related to research that suggests they may lead to an increased risk for suicide and self-
harm (Fergusson et al., 2005; Gunnell, Saperia, & Ashby, 2005).  Ultimately, although 
many factors must be considered such as potential presence of co-morbid mood disorder, 
as well as the client’s tolerance for potential side effects and long-term commitment to 
psychotropic intervention, antidepressants should not be consider a treatment option that 
is free of risk (American Psychiatric Association, 2009).     
In regards to benzodiazepines, most survey participants (n=33, 86.8%) rated it as 
the least safe medication for treating panic disorder.  Additionally, most respondents also 
indicated agreement (strongly agree and somewhat agree response figures collapsed) that 
benzodiazepines build dependency (n=42, 91.3%), that some clients may abuse or sell 
their benzodiazepine prescription medications (n=43, 93.4%), and that clients prescribed 
benzodiazepine medications for their panic disorder may not attend psychotherapy 
appointments regularly” (n=35, 76.1%).  Although providing a measurement of the 
number of clients selling prescription benzodiazepines or missing therapy sessions was 
outside of the scope of this study, the respondents’ level of agreement on these statements 
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clarifies several perceived risks associated with benzodiazepines.  Their concerns related 
to substance dependency, decreased therapy attendance, and the potential for clients to 
sell that medication also appeared to highlight a potential need for adjustments in agency 
treatment guidelines related to prescribing benzodiazepines for panic disorder.  For 
example the agency may consider having clients start with psychotherapy services only 
instead of starting with a combined therapy and pharmacological modality.  Additionally, 
if it is determined that a client might benefit from adjunctive pharmacological treatment, 
practitioners should consider prescribing SSRIs or SNRIs as first line medications instead 
of benzodiazepines as suggested by the American Psychiatric Association’s Panic 
Disorder Treatment Guidelines (American Psychiatric Association, 2009).    
 Furthermore, concerns about the safety of benzodiazepines are supported by 
research that shows individuals that are taking benzodiazepines are at an elevated risk for 
motor vehicle accidents, and in the case of geriatric clients, falls and fractures (French, et 
al., 2005; Kelly, Darke, & Ross, 2004; Landi, et al., 2005).  These safety issues are likely 
related to the commonly reported side effects of benzodiazepines, which include 
sedation, fatigue, ataxia, slurred speech, memory impairment, and weakness (Physician’s 
Desk Reference, 2007).  Additionally, the use of benzodiazepines for more than 2 to 3 
weeks results in physiologic dependence, and abrupt cessation of benzodiazepines can 
lead to dangerous side effects including depression, suicidal behavior, psychosis, 
seizures, and delirium tremens. Although a physician managed gradual taper is 
recommended, clients often have great difficulty discontinuing benzodiazepine 
medications due to withdrawal and rebound panic symptoms (Fava, Zielezny, Savron, & 
Grandi, 1995; Klein, Colin, Stolk, & Lenox, 1994; Roy-Byrne, et al., 2003).  In sum, the 
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concerns of this study’s participants about the safety of prescribing benzodiazepines for 
the treatment of panic disorder appear to be well founded.  
Overall, more respondents chose antidepressants (n= 17, 45.9%) over 
benzodiazepines (n=11, 29.7%) as the most effective medication for treating panic 
disorder. However, ratings for safety for the two medications were not equally distributed 
in the population when analyzed by discipline cohorts, and there was a significant (p = 
.035) relationship between discipline and perceived safety of different classes of 
medications. While most participants (87%) from the social worker, counseling, and 
medical disciplines appeared to favor antidepressant medications in regards to safety, 
over half (60%) of the participants from the psychologist group endorsed neither 
medication as the safest approach for treating panic disorder. This finding suggests that, 
unlike the other cohorts, the psychologists did not believe psychotropic medications are a 
safe treatment intervention for panic disorder, and their preferences will be better 
clarified by in the discussion of therapy approaches.   
On a related item asking if participants agreed that antidepressants were safe and 
effective for treating panic disorder, there were significant differences between discipline 
(p=.048) and educational level groups (p=.013).  Specifically, participants with an 
associate, master, or doctorate degree, indicated more agreement with that item than 
those with a bachelor’s degree, and the counseling and medical groups indicated a greater 
degree of agreement than the psychologists.  Psychologists also differed significantly (p. 
= .008) from all  other discipline cohorts in their greater level of agreement with the 
statement, “benzodiazepine medications interfere with successful psychotherapy.”   
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Therapies.  Overall results of items that asked about different therapy treatment 
approaches for panic disorder revealed a strong preference for cognitive behavioral 
therapy among most participants. For example, when asked which therapy approach was 
safest and which was most effective, the majority of participants chose cognitive-
behavioral therapy, over behavioral therapy, panic focused psychodynamic 
psychotherapy, and emotion-focused psychotherapy.  Research supports the participants’ 
views that cognitive-behavioral therapy is a safe and effective treatment for panic 
disorder; however, it also suggests that behavioral therapy and panic focused 
psychodynamic psychotherapy are safe and effective treatment options as well.  Most 
respondents also indicated that cognitive-behavioral therapy was the most similar therapy 
approach to their own, and the one with which they had the most training and experience.  
Panic focused psychodynamic psychotherapy was the least familiar approach for most 
survey participants, and more respondents also chose it as the least effective therapy 
approach for treating panic disorder.  Taken together, these findings seem to indicate that 
the amount of knowledge, training, and experience that a clinician has is likely to affect 
the perceived safety and effectiveness of that approach.   
Upon further examination, when participant responses for the safest and most 
effective therapy were analyzed by discipline there was a significant difference (p = .047) 
found between cohorts.  Specifically, the endorsements of participants from the medical 
group were divided equally between panic focused psychodynamic psychotherapy and 
cognitive behavioral therapy, while participants from the other discipline cohorts showed 
a stronger preference for cognitive-behavioral therapy in regard to safety.  When it is 
considered that medical training models are more likely to ascribe to psychodynamic 
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psychotherapy approaches, this finding appears to provide further support to the 
previously stated interpretation that there is a relationship between training/familiarity 
and perceived safety and effectiveness of a therapy approach.  
Another highly significant difference (p = .005) among disciplines was found 
regarding the statement: “When psychotherapy has been effective for patients with panic, 
they will not tend to relapse.”  The psychologist group, who likely has the most training 
and familiarity with therapy, was significantly more likely to agree with this statement 
than the medical and social work groups. Again, this finding appears to support a link 
between familiarity and perceived efficacy. Additionally, it should be noted that research 
suggests that although individuals with panic disorder are likely to experience recurring 
cycles of symptom exacerbation, it is a very treatable and manageable mental health issue 
(American Psychiatric Association, 2000; World Health Organization, 1998).  Thus, there 
may be some misconceptions about the nature of panic disorder among other disciplines, 
and future agency trainings should address any knowledge gaps about the treatability of 
panic disorder.  This agency may also want to consider responding to the needs of clients 
with panic disorder with an “episodes of care” approach as opposed to a continuous care 
model, by predicting chances for symptom re-emergence and encouraging clients to 
return for refresher sessions during periods of symptom exacerbation.   
Regarding behavioral therapy that emphasizes exposure and desensitization, an 
interesting difference was noted in the perceived safety and effectiveness of that approach 
among the survey respondents.  The vast majority (93. 4%) of participants indicated at 
least some level of agreement with the statement: “behavioral therapy is a safe and 
effective approach for treating panic disorder.” More specific items revealed that about 
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23.3% of respondents ranked behavioral therapy as the most effective therapy approach; 
however, behavioral therapy was also selected by more participants (46.2%) as the least 
safe of therapy approaches.  This appears to imply a perception that behavioral therapy 
interventions including exposure and desensitization are effective, but not necessarily 
safe.  These findings are at odds with current literature on treating panic disorder that 
indicates progress in managing panic attacks is actually attributable to exposure and 
tolerance building, whether in a behavioral or cognitive behavioral model (Arch,  Ayers, 
Baker, Almklov, Dean, & Craske, 2013; Craske, & Vervliet, 2013).  One possible 
explanation for the concerns about safety expressed by participants in this study may be 
due to their own discomfort with encouraging clients to participate in exposure 
techniques that can be distressing initially.  Although both therapists and clients may be 
reluctant to engage in behavioral therapy interventions initially, there is no evidence of 
that these practices are unsafe, and much evidence that it is ultimately highly beneficial in 
building tolerance and decreasing panic.      
Combination Treatments. The next section of survey response pertained to the 
combination treatments versus therapy or medication alone for the treatment of panic 
disorder. On these survey items most participants favored an antidepressant and therapy 
combination for the treatment of panic disorder in regards to safety and effectiveness 
(78.9% and 57.9% respectively). Additionally, the majority of respondents selected 
medication alone as the least safe (63.2%) and least effective (60.5%) of the approaches 
outlined. Although the participants of this study conveyed a common sentiment in their 
marked preference for a combination of medication and therapy for the treatment of panic 
disorder, research does not support an advantage to this approach.  Studies have 
 
81 
 
repeatedly demonstrated that cognitive-behavioral therapy alone has comparable efficacy 
to cognitive-behavioral therapy with an antidepressant for the treatment of panic disorder 
(Brown & Barlow, 1995; Barlow, Gorman, Shear, & Woods, 2000 ; Craske, Brown, & 
Barlow, 1991; Fava, Zielezny, Savron, Grandi, 1995).  Furthermore, it also suggests that 
cognitive-behavioral therapy without adjunctive pharmacological treatment is most likely 
to produce durable reduction in panic symptoms.  Additionally, Milrod et al. (2007) 
demonstrated promising preliminary findings with their use of panic-focused 
psychodynamic psychotherapy.     
The responses for least familiar and most familiar combination of treatments 
differed significantly (p = .004 and p = .003 respectively) between disciplines.  While the 
other disciplines appeared to be most familiar with therapy and medication or all of the 
combination treatments, the psychologists were most familiar with a therapy only 
approach.   Similarly, the medicine group indicated least familiarity with the therapy only 
approach, while the psychology and counseling groups appeared to be the least familiar 
with a medication only approach.  The participants from the psychology group also 
differed significantly (p = .017) from the other discipline groups by indicating a stronger 
level of agreement with an item stating that therapy alone is a safe and effective treatment 
approach for panic disorder.    
The differences among disciplines outlined above may just be another example of 
how individuals will tend to look more favorably on innovations with which they have 
the most exposure and experience (Rogers, 2003).  Psychologist are likely to have the 
most experience and training in therapy, while the medical group (psychiatrists and 
nurses) are more  likely to have the most experience in working with clients who receive 
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medications for their symptoms. This difference in job responsibilities may also allow 
psychologists to see more gains from therapy due to their primary role as therapy 
providers.  Furthermore, the literature appears to support the notions that therapy alone 
can produce comparable initial results and superior long-term results in the treatment of 
panic disorder (Otto, Smits, & Reese 2006).  
General Opinions.  The general opinion items on the survey indicated that the 
majority of participants felt well-trained and competent t in their panic disorder treatment 
practices.  For example, the majority of participants surveyed indicated that they had 
received training in treating panic disorder through readings (71.1%), coursework 
(62.2%), and supervision (51.1%).  Additionally, most also felt they had enough 
knowledge and  training about panic disorder treatment (84.7%) and thought their own 
and the agency’s treatment practices were safe and effective (93.2% and 93.3% 
respectively).  It should be noted that a limitation to the survey method used assess the 
participants’ knowledge base was that it involved self-report, and not an actual test of 
competency for panic disorder treatment strategies.  Therefore, there is a possibility that 
the respondents may have felt a desire to present favorably or believed that they were 
better informed than they actually were. Thus, this finding should be interpreted with 
those potential sources of bias in mind.   
However, many participants also indicated areas of training and treatment 
practices that might benefit from improvement. For example, participants with an 
associate or bachelor’s degree were significantly less likely to indicate that they felt they 
had the knowledge and training that they needed to help clients with panic disorder (p = 
.024), than those from higher educational attainment cohorts.  This finding suggests there 
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might be an opportunity for more expert clinicians within the organization to share their 
knowledge about panic disorder treatments with those who are expressing further training 
needs.  Participants with a bachelor degree were also significantly (p = .021) more likely 
to agree with the item stating: “Our center needs to revise its approach to treating panic 
disorder.”  Specifically, one potential change in treatment guidelines that garnered 
support from the majority of overall respondents (78.3%) was that the agency should 
refer clients with panic disorder for psychotherapy prior to considering them for referral 
for medication.  
Phase Two Discussion: Database Review 
The second phase of this study consisted of analyzing 3 years of client data in 
order to gain insight into the agency’s current treatment practices and related client 
outcomes. Despite current clinical practice guidelines that recommend antidepressants be 
used as the first-line medication for the treatment of panic disorder, of the 138 clients 
identified as having pure panic disorder, 119 were receiving a combination of 
benzodiazepines and therapy services (American Psychiatric Association, 2009).  This 
incongruence in treatment guidelines and actual practices was consistent with a 
longitudinal study that suggested most patients treated for panic disorder were still 
receiving benzodiazepines (Bruce, Vasile, & Goisman, 2003).   
As previously mentioned, the necessity of an admission and termination date in 
order to calculate duration of treatment and differences in pre and post treatment GAF 
scores, led to a small sample size (n=25).  Of these participants, five included in the 
sample were in the therapy only treatment group, and 20 received therapy and 
benzodiazepine medication for the treatment of panic disorder. The small subsample 
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groups in this study decreases its statistical power, and a type II error, or failure to detect 
differences when they exist, may be more likely to occur (Cleophas,Zwinderman, 
Cleophas, Cleophas, & Cleophas-Allers, 2012). This limitation should be kept in mind 
when considering the discussion below that explores differences and similarities between 
treatment groups related to outcome variables including outcome scores and treatment 
duration.  
Outcomes.  The mean difference in pre and post GAF scores for the therapy only 
and the combination therapy and benzodiazepine medication treatment groups were very 
similar (Ms = 7 and 7.5 respectively), and statistical analysis (independent t-test) revealed 
no significant (p = .627) difference between the two groups on this outcome variable.  
This is consistent with research showing that therapy alone is comparable to therapy with 
medication for treating panic disorder (Barlow, Gorman, Shear, & Woods, 2000; 
Schmidt, & Smith, 2005; Westra, Stewart, & Conrad, 2002).  Since there is no apparent 
benefit to adding benzodiazepine medication to therapy when treating panic disorder, the 
participating agency should consider whether combination treatment is merited for most 
panic disorder only cases considering the added costs and safety risks that come with 
prescribing medications. 
A limitation to this study is the lack of measurement for maintenance of progress 
after treatment has ceased.  It would be interesting to see if there were any differences in 
the durability of treatment gains at a 1-year follow up.  Previous researches have 
suggested that the concurrent use of benzodiazepines with therapy can decrease long-
term treatment gains and maintenance (Barlow, Gorman, Shear, & Woods, 2000; Brown 
& Barlow, 1995; Craske, Brown, & Barlow, 1991; Craske, & Vervliet, 2013; Fava, et al., 
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1995; Westra, et al., 2004).  Differences in treatment durability have been attributed to 
interference of benzodiazepines with the consolidation of learned psychoeducational 
material and rebound panic symptoms in the cases of clients who cease medication.  
Since these and other factors may affect long-term maintenance of treatment progress the 
participating agency may want to consider using a follow up outcome measure for clients 
periodically after termination.   
Duration.  The next outcome variable that was analyzed for differences between 
the combination therapy and benzodiazepine medication versus the therapy only 
treatment group was duration of treatment in months.  There was a significant (p = .019) 
difference between groups on this variable, and the combination group clients were in 
treatment many more months than the therapy only group on average (Ms=29.95 and 
19.6 respectively).  This difference suggests that benzodiazepine medication may be 
slowing clients’ progress.  This finding could be related to previously mentioned research 
that indicates that benzodiazepine medication interferes with recall of psychoeducational 
material that is helpful in decreasing symptoms of panic disorder (Westra, et al., 2004).  
It may also suggest that benzodiazepines interfere with psychotherapy by decreasing 
symptoms during in vivo experiences of anxiety and panic, thus decreasing the client’s 
ability to build tolerance for these symptoms through unfiltered exposure. 
Additionally, it may be that clients attribute progress to the benzodiazepine 
medication, thus missing potential opportunities to build self-efficacy in managing their 
panic disorder and reach therapeutic goals.  
A limitation for this study is the lack of related treatment information from which 
to draw inferences about this significant difference in treatment duration.  For example, 
 
86 
 
factors such as number of sessions, type of therapy provided, or patient demographic 
variables may also co-vary with the treatment modality to affect duration.  Additionally, 
this agency only had initial and termination GAF scores for clients who had already 
terminated treatment. Therefore, both groups of clients may be making the same amount 
of progress in the same amount of time, but those in the combination group may be 
continuing treatment longer for other reasons such as continued medication prescriptions 
or to support a disability claim.   Future researchers may want to design studies that have 
more points of measurement for outcome than just pre and post treatment and condition 
specific inventories such as a Beck Anxiety Inventory (BAI; Beck, & Steer, 1993) or 
Panic Disorder Severity Scale (PDSS; Shear et al., 1997; Shear & Maser, 1994) in order 
to clarify the nature of potential treatment duration differences. Additionally, the 
participating agency may wish to increase frequency of assessing treatment outcomes and 
share information with clients about progress in order to foster efficiency for the agency 
and feelings of self-efficacy and hope for clients. In addition to a GAF score, which may 
have limited utility and poor inter-rater reliability, they should consider utilizing an 
outcome measure that can provide more information on treatment progress such as the 
Outcome Questionnaire-45 (OQ-45; Lambert et al., 2004) or the Brief Symptoms 
Inventory (BSI; Derogatis, 1993)  
Overall, the results of the survey and database review for this study were 
consistent with many of the potential issues identified at the outset of this project.  For 
example, survey participants voiced concerns about safety and dependency issues related 
to benzodiazepine prescription for panic disorder. Additionally, the respondents indicated 
concerns about therapy attendance rates for clients receiving those medications, and they 
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appeared to favor a shift in agency referral practices that would have clients enroll in 
therapy services prior to consideration for treatment with medication.  These findings 
suggest an identified problem at the participating agency, and client care personnel are 
likely to be receptive to information about innovative practices to address these dilemmas 
(Rogers, 2003).  As Schulz and Greenberg (1995) suggested, the key groups at this 
agency including discipline and educational level cohorts had somewhat different 
perceptions of current practices and possible innovations in regard to potential benefits 
and consequences.  Thus, it will be important to encourage adoption of change within 
these groups in a manner that suits the unique perspectives they revealed in their survey 
responses.  Due to the different interests and opinions expressed between groups, it will 
be especially important to identify innovation champions within each subgroup (Rogers 
2003:2004). Innovation champions are charismatic individuals that can address the 
resistance among their peers and increase the likelihood of success of a proposed 
innovation.  Due to their attractive interpersonal styles they are also key individuals 
through which to disseminate knowledge and information about the various innovative 
treatment options that might be beneficial for this agency.  Further specific 
recommendations for this agency and other like it will be discussed in the concluding 
section about clinical implications.  
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Clinical Implications 
This study is a case in point of one agency’s knowledge, skills, attitudes, and 
practices regarding the treatment of panic disorder. Specifically, it showed that although 
differences in beliefs about the effectiveness and safety of treatments were often seen 
among providers from different disciplines, differences in client outcomes due to 
treatment practices where minimal. It provided support for the existing literature base on 
panic disorder, and raised further concerns about the potential drawbacks of adjunctive 
psychotropic interventions for panic disorder, including the possibility of prolonged 
treatment duration.  It is a translational research piece that adds to the existing literature 
on panic disorder treatment by presenting findings from a multidisciplinary community 
mental health setting.   From its inception, it was intended that the findings from this 
study be both useful for the participating agency and generalizable to other organizations 
hoping to implement best practice standards for treating panic disorder.  
The theme of comfort and confidence in the treatment practices which were most 
familiar presents an opportunity for consciousness raising work within the participating 
agency (Prockaska & Diclemente, 1984).  The goals of this consciousness raising should 
be to increase self-efficacy in applying innovative panic disorder treatment practices, as 
well as shifting the decisional balance by increasing perceived positive outcomes for 
learning and applying those strategies (Bandura, 1977; Janis and Mann, 1977).  
Consciousness raising strategies can promote motivation and persistence for change, and 
safeguard against resistance or relapse (Levesque, Prochaska, & Prochaska, 1999).  One 
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example of how this strategy could be applied at the participating agency would include 
offering information about the current research and treatment standards that are not 
currently being met.  Additionally, the client care employees would also likely benefit 
from hearing more about the variety of empirically validated treatment strategies that are 
available for treating panic disorder such as cognitive behavioral therapy, exposure-based 
behavioral therapy, and panic focused psychodynamic psychotherapy.     
The review of professional practice standards and agency treatment regarding 
psychotropic interventions for the treatment of panic disorder should address the two 
specific problems identified:  (a) The number of benzodiazepine prescriptions for panic 
disorder appears to be inconsistent with current professional treatment standards, and 
clinicians should consider ways of helping clients taper off those medications. Some may 
benefit from a different medication if mood issues are present, and others may benefit 
from gaining better control of symptoms and increased tolerance through therapeutic 
change. (b) The process for referral in the participating agency should help clients and 
clinicians capture opportunities for therapeutic change prior to adding a medication.  
Specifically, clients should be given the opportunity to benefit from therapy before being 
referred for medication. By applying a least invasive intervention approach, risks, 
expenses, and potential side effects can be avoided for many clients who would receive 
comparable treatment benefits from therapy alone.  
It appears that the survey participants already have some awareness of the 
agency’s current needs with regard to adopting more innovative panic disorder treatment 
strategies, and Roger’s (2003; 2004) work on diffusion of innovations suggests that they 
can be assisted in working through the first stage of diffusion by the change agents within 
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their organization.  If change agents such as team leaders can help others increase 
knowledge and exposure to other therapeutic strategies, they may make them more 
comfortable with adopting those new strategies and recruit more stakeholders in 
promoting change.  Specifically, this agency and others like it should consider offering 
training opportunities such as in-services, sponsored convention attendance, or 
continuing education courses regarding a variety of effective treatment approaches such 
as cognitive-behavioral therapy, panic focused psychodynamic psychotherapy, and 
behavioral therapy.   A few influential team members could be given “advanced training 
in treating panic disorder.” When the advantages of their newly learned skills are shared 
with others at the agency, others will be more likely to consider adopting innovative 
treatment strategies and become future stakeholders in this change process.   
This dissertation was a translational research piece that was developed to compare 
professional treatment standards with actual practices at a large metropolitan community 
mental health agency.  It was designed in hopes of clarifying potential obstacles and 
dilemmas in implementing innovative and best practice treatment standards in a real 
world setting. A database review confirmed high rates of benzodiazepine prescriptions 
for clients with panic disorder.  Analysis revealed that, consistent with previous research, 
clients receiving a combination of benzodiazepines and therapy did not have improved 
outcomes.  Furthermore, the results of this study showed a trend of prolonged treatment 
duration for clients prescribed benzodiazepines for panic disorder.  A survey also 
provided insight into the current knowledge, skills and attitudes of client care personnel 
at the participating agency regarding panic disorder treatment.  The results of this survey 
indicated that clinicians have identified problems with agency treatment practices related 
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to the prescription of benzodiazepines for panic disorder treatment, and they would likely 
be open to receiving more information about potential innovative solutions to those 
issues.  Survey results also showed there is an opportunity to increase the knowledge base 
within this agency regarding the variety of efficacious therapy approaches for treating 
panic disorder. Specifically, due to the findings of this current study and review of 
literature regarding the treatment of panic disorder, emphasis on the effectiveness and 
durability of therapy only approaches should be emphasized in applying these results to 
the participating agency and other like.    
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Appendix A:  Phase One, Panic Disorder Treatment Survey 
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Appendix B:  Sanitized Survey Recruitment Script 
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Appendix C:  Record Review Plan 
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Appendix D:  Overall Results of Phase One Survey 
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